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Tuberculosis (TB) is one of the oldest human diseases and also one of the major 
diseases that endangers human's health. With the drug-resistant TB especially multidrug-
resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) dissemination, the 
treatment of TB faced up more difficulties [1]. 
Thereby, search for new anti-TB drug with high activity at low concentration is urgent 
need which can be achieved using Computer-aided drug design. Computer-aided drug design 
is a powerful tool for designing new drug or modifying the existing one. These methods are 
dependent on bioinformatics tools, applications and databases, simple, non expensive, and 
accelerate the process of designing novel and potent molecules with desired biological 
activity [2, 3]. The significant gain in knowledge and structure information of both biological 
macromolecules and small molecules facilitate CADD to be extended and broadly applied to 
almost every stage in the drug discovery and development stage, from target identification 
and validation, to lead discovery and optimization, and preclinical tests.  
Molecular mechanics MD simulation has become one of the most influential tools to 
predictthe conformation of small molecules, as well as for modeling, conformational changes 
within a biological target upon binding bysmall molecules [4, 5]. Semi-empirical methods 
such as ab initio methods or density functional theory DFT are most often used to providethe 
expected optimized parameters for molecular mechanics calculationsand to estimate 
important electronic properties (electrostatic potential, polarizability, etc.) of the drug 
candidate that influence itsbinding affinity [6]. 
In this thesis, we have used different CADD approaches to investigate the detailed 
structural mechanisms of the target proteins and search for inhibitors, the detailed structural 
mechanisms of the target proteins and search for inhibitors. 
Ligand-based drug design (LBDD) is an appropriate method to apply if there are 
experimentally active compounds that bind to the biological target of interest.Quantitative 
structure–activity relationship (QSAR) can be used to derive a correlation between 
theoretically calculated properties of molecules and their experimentally obtained biological 
activity. The resulting correlation derived from QSAR can in turn be further used to predict 







Structure-based drug design (SBDD) virtual screening involves using the known 3D 
structure of a target protein to predict binders, through the process of the docking.  Docking is 
the computational determination of a binding pose and" binding free energy "of a ligand to a 
receptor. Determination of the binding pose and" binding free energy" is crucial for 
understanding the important ligand -receptor interactions and mechanism of action, thus 
valuable in the design of new drug .In molecular docking thousands of possible poses of a 
ligand inside a receptor cavity are tried and evaluated; the pose with the lowest energy score 
is predicted as the "best match", the binding pose [7]. 
In silico tools, it is possible to accelerate the drug-discovery process by modeling the 
most relevant ADMET properties [8]. A molecule could be too toxic, too quickly eliminated 
from the body, possess fast metabolic reaction, unstable, too challenging to synthesize in 
large volume, or too expensive to produce. 
This manuscript consists of four chapters. : 
The first chapter represents a bibliographic review describing the tuberculosis 
(Treatment and Prevention of Tuberculosis, Mycobacterium tuberculosis,Serine/threonine 
protein kinase B). 
The second chapter describes the different Computational methods in drug 
discovery(Quantitative structure-activity relationships (QSAR), Molecular Docking). 
The third chapter comprises a various‘multi-parameter optimization’ (MPO) 
approaches such as lipophilicity profile, rules of thumb and calculated metrics methods used 
to highlight the Structure Activity/Property Relationships of a bioactive series of amino-
pyrimdines, and we have studies Quantitative relationship (QSAR) between physiochemical 
properties and biological activity ( work published in: Journal of Bionanoscience , Vol 11(4), 
31–309,2017 and Journal of Turkish Computational and Theoretical Chemistry 
(TC&TC),Vol 2(2),16–27, 2018). 
Thefourth chapter we have studies Structure-based virtual screening usingdocking 
analysis and (ADMET)absorption, distribution, metabolism and toxicity study forward few of 
them as plausible lead molecule or a novel class of drugswith enhanced pharmacological 
properties(work published in: press in the journal : Journal of Fundamental and Applied 
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The disease of tuberculosis 
 





 Tuberculosis (TB) is a contagious but curable infectious disease caused by the 
pathogen, Mycobacterium tuberculosis (Mtb) and is again becoming a major cause of 
mortality worldwide. The Mtb and its pathogenic strains cause infection mainly in the 
oxygen-rich macrophages of the lungs. The main causes for the resurgence of this once 
nearly eradicated infectious diseases are the reduction in the emphasis on TB control 
programs, the declined socioeconomic standards and also the emergence of immune 
deficiency states like, AIDS. Despite the fact that TB has been recognized for thousands of 
years and its etiological agent has been identified since the earliest days of medical 
microbiology, TB continues to loom as one of the largest infectious diseases, with 
enormous global burden of morbidity and mortality. TB thrives in impoverished or 
malnourished communities; individuals weakened by immunological deficiencies and 
situations where healthcare delivery is poor [1, 2]. According to global tuberculosis report 
by World Health Organization (WHO), in 2017, an estimated 10 million people developed 
TB and 1.3 million deaths among HIV-negative people and almost 300000 deaths among 
HIV-positive people. 
 The geographic incidence of infection and therefore disease burden varies greatly. 
Most of the estimated number of cases in 2017 occurred in the South-East Asia Region 
(44%), the African Region (25%) and the Western Pacific Region (18%); smaller 
proportions of cases occurred in  Eastern Mediterranean Region (7,7%), Region of the 
Americas (2,8%) and European Region  (2,7%). The 30 high TB burden countries 
accounted for 87% of all estimated incident cases worldwide, and eight of these countries 
accounted for two thirds of the global total: India (27%), China (9%), Indonesia (8%), the 
Philippines (6%), Pakistan (5%), Nigeria (4%), Bangladesh (4%) and South Africa (3%) of 
the global total shows estimated TB incidence rates by country in 2017 (Figure I.1) [1]. 
Furthermore, the development of multidrug-resistant tuberculosis (MDR-TB) and 
extensively drug-resistant tuberculosis (XDR-TB) strains, together with the spread of risk 
factors such as human immunodeficiency virus (HIV), acquired immunodeficiency 
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syndrome (AIDS) and diabetes [3], continue making Mtb a health concern in developed 
countries and strengthened the urge to develop new treatment infection strategies. 
 
Figure I.1: Estimated TB incidence rates, 2017. 
 
1.2 TB Pathogenesis 
Mtb infection occurs when few tubercle bacilli dispersed in the air from a patient 
with active pulmonary TB reach the alveoli of the host. Here, Mtb is quickly phagocytized 
by professional alveolar macrophages that most often can kill the entering bacteria thanks 
to the innate immune response (Figure I.2.) [4]. If the bacilli can survive this first line of 
defense, it starts actively replicating in macrophages; diffuse to nearby cells including 
epithelial and endothelial cells, reaching in few weeks of exponential growth a high 
bacterial burden. During these early steps of infection, Mtb can diffuse to other organs 
through the lymphatics and by haematogenous dissemination where it can infect other cells 
[5]. 
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Thereafter, once the adaptive immune response kicks in, migration to the site of 
primary infection of neutrophils, lymphocytes and other immune cells form a cellular 
infiltrate that later assume the typical structure of a granuloma [6]. Fibrotic components 
cover the granuloma that becomes calcified such that bacilli remain encapsulated inside 
and protected by the host immune response. This primary lesion, classically termed the 
Ghon complex [7], was thought to be the “sanctuary” of Mtb during latent infection, with 
bacilli persisting in a dormant, non-metabolically active state, for years, decades, or most 
often for lifetime. In this scenario, when, during latent infection, for unknown reasons, 
bacilli would start replicating inside this primary lesion, active disease would ensue [8].  
A major corollary of this hypothesis, with relevant pathophysiological and clinical 
implications, was that reactivation of TB originated from this very primary site of 
infection. This hypothesis was challenged since the early 20th century, when it was shown 
that viable and infective bacilli were found in unaffected portion of lung tissues of infected 
guinea pigs or human necropsy rather than from the central core of the tuberculous lesions 
[9, 10].  
 
Figure I.2: TB pathogenesis. 
 Chapter I                                                                                  The disease of tuberculosis                    
9 
 
1.3 Symptoms  
Many of the worst symptoms of active tuberculosis arise as a direct result of the 
extensive tissue damage that the bacteria do to your lungs . Typical signs and symptoms of 
active tuberculosis include a bad dry cough lasting for more than three weeks that may 
cause you to cough up bloody sputum. You are also likely to experience night sweats, 
fever and weight loss (the reason why historically tuberculosis was called “consumption”) 
as your body tries to fight off the infection.  
For about one in five people, the infection is so severe that cavities begin to form 
within the lung tissue. If these areas start to bleed, tuberculosis bacteria are able to enter 
the blood stream. If this happens, they can travel to other parts of your body, causing 
additional symptoms. A tuberculosis infection outside of the lungs is called an extra-
pulmonary tuberculosis infection and most commonly occurs in your lymphatic system, 
your genitourinary system, and/or in your bones and joints. However, in some cases extra-
pulmonary tuberculosis is disseminated, which means the infection has spread widely 
throughout whole body [11].  
1.4 Treatment and Prevention of Tuberculosis 
1.4.1 Treatment of Tuberculosis 
Treatment of TB is used not only to cure the disease but also to interrupt the 
transmission and to prevent relapse (most relapses occur within 6-12 months after the end 
of therapy) [12]. In 1994, the WHO introduced the Directly Observed Treatment Short 
Course (DOTS), a strategy for the detection and treatment of TB, in which patients are 
observed to take each dose of anti-TB medication, until the end of therapy [13]. Monthly 
sputum specimens are then taken until 2 consecutive specimens are negative. However, the 
effectiveness of DOTS is facing new challenges due to the increase of MDRTB and the 
emergence of XDRTB. This lead to a new strategy called DOTS-plus, a comprehensive 
management initiative built upon the DOTS strategy with the goal of preventing further 
development and spread of MDRTB [14, 15]. 
Treatment can be divided into first-line and second-line drugs : the first-line drugs 
used are INH (Isoniazid), RIF (Rifampicin), pyrazinamide (PZA), ethambutol (EMB) and 
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streptomycin (STR) and the second-line drugs include fluoroquinolones, aminoglycosides 
such as kanamycin and amikacin, cyclic peptides like capreomycin, D-cycloserine, 
ethionamide, and r-amino salicylic acid. Each treatment regimen for pulmonary TB caused 
by susceptible organisms has an initial 2 months intensive phase with INH, RIF, PZA and 
EMB, followed by a continuation phase with INH and RIF for 4 to 7 months. STR can be 
used as an interchangeable drug with EMB in the initial phase of treatment. However, STR 
is only recommended to be interchangeable with EMB when the organism is known to be 
susceptible to the drug or the patient is from a community in which STR resistance is 
unlikely [16,13] 
1.4.2 Mechanisms of Drug Resistance  
Drug resistance is a natural phenomenon and the mechanisms via which bacteria 
develop resistance are diverse and complex. M. tuberculosis resistance occurs due to its 
highly hydrophobic cell wall (Figure 1.2) that is impermeable to most drugs and the 
resistance determinates encoded by its genome [17, 18].  
The resistance to RIF is due to mutations in the rpoB gene which is responsible for 
producing the beta subunit of the DNA-dependent RNA polymerase. However, there is a 
small fraction of resistant bacteria that does not exhibit this mutation suggesting there are 
other mechanisms of RIF resistance .INH is a pro-drug that is activated by an enzyme 
called KatG and it inhibits an enzyme that is involved in fatty acid biosynthesis called 
InhA. Resistant to INH occurs due to mutations in the either katG or inhA genes [19]. 
Streptomycin resistance occurs due to mutations in the 16s rRNA genes rrs and rpsL, the 
gene encoding ribosomal protein S12 [20]. ETH resistance is acquired via the mutations in 
the embB gene that encodes for the arabinosyl transferases that is inhibited by ETH [21].  
Resistance to fluoroquinolones is due to specific mutations in the gyrA and gyrB 
genes that encode for DNA gyrase A and B subunits respectively [22]. Aminoglycosides 
have the same mechanism of resistance as described for streptomycin. Since the MOA of 
polypeptides has not been characterized, the mechanism of resistance is not fully 
understood; however it also changes the 16s rRNA and thus may confer cross-resistance 
from streptomycin [19]. Despite the impact of global tuberculosis and the prevalence of 
drug resistance, no new classes of drugs have been approved for Tb treatment by the US 
Food and Drug Administration since 1972 [23]. There is an urgent need for new and 
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alternate drugs to target Tb with novel MOA to prevent cross-resistance from current anti-
tubercular drugs [24]. 
1.4.3 Prevention of the Tuberculosis  
Beside the treatment of both open and latent form of tuberculosis, i.e. intervention on 
infected patients, there is a question of prevention of mycobacterial infections. The 
combination of a new highly effective pre-exposure vaccine with a more effective 
preventive therapy would potentially have a dramatic effect on incidence. A highly 
effective post-exposure vaccine may have the same effect as a preventive treatment. 
Unfortunately, these methods are not yet available [25]. 
BCG vaccine is currently the most widely used only available vaccine against TB. It 
has been administered up to three billion people without serious complications. Although it 
displays some advantages (easy administration, it can confer immunity for a long period, a 
very efficient adjuvant for immunity induction, a low cost), recent molecular analysis have 
revealed that genetic modifications formed subs trains along time and a complete virulence 
acquisition is also suspected for the vaccine. Another problem is that there can be a gradual 
loss of T-memory cell population during in the course of time. Regrettably, BCG 
vaccination has had the limited impact on the global burden of TB. Although vaccine has 
been effective to prevent severe and fatal forms of TB in young children (e.g. meningeal 
form), it does not protect against pulmonary TB in adults sufficiently. Since the efficacy 
varies from zero to 80 %, the new improved vaccine is searched constantly [26, 27]. 
A second approach consists of thorough prevention leading to the reduction of such 
factors, which increase the risk of progression from infection to disease; HIV, the 
malnutrition, smoking, diabetes mellitus and alcohol misuse are individual risk factors that 
can double or triple the risk of development of active tuberculosis. Indoor air pollution is 
an additional possible causal factor. A wide range of disorders (e.g. silicosis, malignant 
diseases and chronic systemic illnesses) and immunosuppressive treatment are established 
risk factors for TB; some other common situations were proposed, but very little research 
has been done to test these hypotheses (chronic helminthes infections, depression, mental 
illness, pregnancy and the postpartum, outdoor air pollution) [25]. 
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2. Mycobacterium tuberculosis  
2.1  General Characteristics  
Tuberculosis (TB) is caused by the infectious agent known as Mycobacterium 
tuberculosis (MTB). This rod-shaped bacterium, also called Koch's bacillus, was 
discovered by Dr. Robert Koch in 1882 [28]. MTB is a small, slow-growing bacterium that 
can live only in people. It is not found in other animals, insects, soil, or other nonliving 
things. MTB is an aerobic bacterium, meaning it needs oxygen to survive. For this reason, 
during active tuberculosis disease, MTB complexes are always found in the upper air sacs 
of the lungs. The bacterium is a facultative intracellular parasite, usually of macrophages, 
and has a slow generation time, 15-20 hours, and a physiological characteristic that may 
contribute to its virulence. The bacteria usually attack the lungs, but MTB bacteria can 
attack any part of the body such as the kidney, spine, and brain. If not treated properly, 
disease can be fatal. It is transmitted from person to person via droplets from the throat and 
lungs of people with the active respiratory disease.  
2.2 Taxonomy 
In the Bacteria Kingdom, Genus Mycobacterium belongs to the Phylum 
Actinobacteria, Order Actinomycetales (Suborder Corynebacterineae) and Family 
Mycobacteriaceae. 
2.3  Classification  
             Mycobacteria can be separated into different groups according to their phenotypic 
characteristics. The most used classification system was created by Runion in 1959 and 
establishes four groups based on culture characteristic, the incubation period required for 
growth and the development of pigmentation in the presence/absence of light [29,30]. The 
first three groups include slow growth mycobacteria that require longer periods of 
incubation (e.g. M. tuberculosis) and the fourth group comprises rapid growth 
mycobacteria that form colonies within seven days of incubation (e.g. M. smegmatis): 
o Group 1 (Photochromogens) – mycobacteria that produce nonpigmented colonies 
When grown in the dark and pigmented colonies only after exposure to light (e.g.: 
M. kansasii, M. marinum). 
o Group 2 (Scotochromogens) – mycobacteria that produce yellow to orange 
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colonies when grown in the dark (e.g.: M. gordonae, M. xenopi). 
o Group 3 (Non-chromogens) – mycobacteria nonpigmented in the light or dark. 
However, older cultures can develop a yellow pigmentation (e.g. M. tuberculosis, 
M. avium, M. bovis, M. ulcerans). 
o Group 4 – rapid growth mycobacteria that have a slight yellow pigment that does 
not intensify after light exposure (e.g. M. fortuitum, M. chelonae). 
2.4 Morphology  
Mycobacteria are typically rod-shaped, non–spore forming, aerobic bacteria, 
classified as acid-fast bacilli. The dimensions of the bacilli have been reported to be 1-10 
μm in length (usually 3-5 μm), and 0.2 -0.6 μm width. Variable morphology can be 
observed when grown on solid media and some species exist as shorter cocci-bacilli or 
curved rods on artificial media [31]. 
The reported morphological variation in M. tuberculosis are classified in two 
categories; i) those which are frequently seen at exponential phase of growth that is rod, V, 
Y-shape, branched or buds , and ii) those that are seen occasionally under stress or 
environmental conditions which are round, oval, ultra-virus, spore like, and cell wall 
defiant or L-forms (Figure I.3) [32]. 
Figure I.3: Morphological variations in M. tuberculosis. (A). Thin section                                 
transmission electron micrograph of Mtb . (B). Scanning electron microscope shows shape 
variation in Mtb at exponential phase of growth. 
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2.5  cell-wall 
The cell wall structure of Mtb (Figure I.4), unique among procaryotes, is associated 
with the pathogenicity of Mtb [34-36]. The richness in high molecular weight lipids 
represents the complexity of the cell wall [38-42]. Unusual impermeable properties of Mtb 
cell wall are thought to be advantageous for the bacilli in stressful conditions of osmotic 
shock and the polymers, covalently linked with peptidoglycan and trehalose dimycolate, 
provide a thick layer involved in Mtb resistance to antibiotics and the host defense 
mechanisms [43]. 
The mycobacterial cell wall consists of a capsule, a core and an inner membrane 
(Figure I.4). The capsule is made up of free lipids and mycolates such as the 
phosphatidylinositol mannosides (PIMs) and lipoarabinomannan (LAM). The core consists 
of peptidoglycan (PG) and mycolic acid connected by an arabinogalactan (AG) 
polysaccharide, collectively called the mycolyl arabinogalactan–peptidoglycan (mAGP) 
complex. And lastly the inner membrane which consists of a lipid bilayer . The presence of 
such a large amount of lipid in the cell wall makes it acid-fast. This is evident when the 
cells are stained with Ziehl-Neelsen stain. They resist decolorization with acid alcohol and 
retain the primary carbol fuchsin stain giving it the characteristic red/pink color. 
 
Figure I.4: The mycobacterial cell wall. 
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3. Serine/threonine protein kinases (STPKs) 
Protein phosphorylation/dephosphorylation is a critical regulatory mechanism by 
which extracellular cues are transduced into cellular responses. Traditionally, two-
component systems comprising a histidine kinase sensor and the associated response 
regulator were thought to be responsible for phosphorProtein 
phosphorylation/dephosphorylation is a critical regulatory mechanism by which 
extracellular cues are transduced into cellular responses. Traditionally, two-component 
systems comprising a histidine kinase sensor and the associated response regulator were 
thought to be responsible for phosphorylation-mediated signaling in prokaryotes [44, 45]. 
Two-component pathways are rare in eukaryotes, and phosphotransferbased signaling 
predominantly involves phosphorylation/ dephosphorylation on serine, threonine, or 
tyrosine residues, often in a cascade.  
The presence of a eukaryotic-like serine/ threonine protein kinase (STPK) in a 
prokaryote was first reported in 1991 (pkn1 in Myxococcus xanthus) [46]. These 
“eukaryotic-like” STPKs play important roles in bacterial cellular processes, including cell 
division, cell wall synthesis, cell metabolism, and dormancy exit. Analysis of the 
Mycobacterium tuberculosis genome sequence suggested the presence of 11 putative 
eukaryotic-like STPKs and three protein phosphatases [47]. Except for PknG and PknK, all 
of these kinases were predicted to have a transmembrane domain [47, 48]. All of the 
kinases possessed the protein kinase “signature” motifs, including 11 conserved 
subdomains as per Hanks’ criteria, and amino acid sequence alignment of these STPK 
family members revealed that 15 catalytically important residues were conserved across all 
of them [48,49].  
The M. tuberculosis STPKs affect key mycobacterial processes: signal transduction 
mediated by PknA and PknB plays an important role in determining cell shape, 
morphology, and possibly cell division ; PknG and PknH influence M. tuberculosis 
virulence, adaptation, and growth within the host [50]; and PknF affects cell division, 
growth rate, morphology, and glucose transport [51]. Recently, Ortega et al. [52] proposed 
a role for PknB as a replication switch in response to hypoxia. They demonstrated that 
PknB activity is necessary for reactivation of cells from the hypoxic state. 
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4. Challenges in the Development of New Drugs  
Along with the socioeconomic and host factors that underlie the serious global 
burden of TB, a fundamental problem that hinders more effective TB control is the ability 
of MTB to persist in the host and to develop drug resistance, often because of poor 
adherence to lengthy therapy. Despite a resurgence of TB, development of new drugs to 
treat the disease has stagnated in the face of numerous scientific and economic obstacles. 
Showing of the superiority of new agents constitutes the most convincing clinical evidence 
of drug efficacy, but in the case of drug-sensitive disease this may be infeasible given the 
high efficacy rates of existing regimens, the need for extended follow-up, and the large 
number of participants required supporting statistical conclusions [53]. 
Primarily, overall funding for TB research in general, and drug discovery in 
particular, remains alarmingly inadequate. TB research is funded in competition with all 
other areas of biomedicine and is clearly not receiving funds commensurate with the global 
dimension of the disease and the probability that untreatable forms of TB will become 
increasingly widespread [54]. Besides, the TB drug market is associated with insufficient 
profit opportunity or investment return to instigate pharmaceutical industries to develop 
new drugs [55]. 
Secondly, it is the lack of access to information, pharmaceutical expertise, 
compounds, and research tools. There would be great value, for example, in a publicly 
accessible database that collected thorough information about screenings of compounds 
and about analyses that indicate which targets in MTB appear to be “druggable.” 
Considering the limited resources for TB drug development, it is critical to avoid repetitive 
efforts, particularly multiple independent journeys to a dead-end. However, the molecular 
mechanisms responsible for mycobacterial dormancy, persistence, and drug resistance are 
not yet fully understood [56]. 
Thirdly, there are a number of constraints that have companies from investing in new 
anti-TB drugs. The research is expensive, slow and difficult and requires specialized 
facilities for handling MTB. There are few animal models that closely mimic the human 
TB disease. Development time of any anti-TB drug will be long. In fact minimum six  
 Chapter I                                                                                  The disease of tuberculosis                    
17 
 
Month therapy will require with a follow up period of one year or more [57].Lastly, the 
challenge of TB drug Research and Development is the long timeline of clinical trials. 
Phase II studies for TB drugs typically require at least two years, and pivotal trials a 
minimum of three years from beginning patient enrollment to finalized study reports. 
Furthermore, the fact that people must be treated with a combination of four drugs, rather 
than with a single drug, means that to replace the current regimen with a totally new three- 
or four-drug regimen by testing the substitution of one drug at a time into the standard 
regimen will require not a minimum of six years, but at least four times six years - over 
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Drug discovery plays an important role in the growth of any pharmaceutical company 
and society, as newer and safer drugs are launched in the market with the sole objective of 
improving the therapeutic value and safety of drugs. The pharmaceutical industry has 
consistently shown that it can discover and develop innovative medicines for a wide range 
of diseases [1]. 
Drug research, as it is called today, began when chemistry had reached the peak of its 
career, allowing chemical principles and theories to be applied to problems outside the 
scope of chemistry, and when pharmacology became an independent scientific discipline 
on its own. By 1870, some of the important foundations of chemistry theory had been laid 
[2, 3]. In the twentieth century, biochemistry had remarkable influence on drug research in 
numerous ways. It was during this period that the concept of targeting enzymes and 
designing drugs as inhibitors came into existence [4].However, the current drug-discovery 
process is very time consuming and expensive and can take up to 12–16 years of 
exhaustive research, huge financial investment, and clinical trials before a molecule can be 
recognized as a drug . 
Despite the diverse research and development (R&D) approaches adopted by 
pharmaceutical companies, the attrition rate is inadmissibly high. One of the factors 
contributing to the high attrition rates is an active compound with unacceptable absorption, 
distribution, metabolism, excretion, and toxicity (ADMET) adverse effects that thus needs 
to be withdrawn from development. This factor represents approximately 50% of all costly 
failures in drug development [6], and it has become widely appreciated that these areas 
should be considered as early as possible in the drug-discovery process [7, 8]. It is evident 
that the pitfall in the current drug-discovery process urges an unconventional approach, 
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2. Computer-aided drug design 
2.1 Introduction 
 Computer aided drug design (CADD) is a multidisciplinary field attracting the 
researchers from information technology, medicine, pharmacology etc. Computational 
tools have become increasingly important in drug discovery and design processes (Figure 
II.1) Methods from computational chemistry are used routinely to study drug-receptor 
complexes in atomic detail and to calculate properties of small-molecule drug candidates. 
Tools from information sciences and statistics are increasingly essential to organize and 
manage the huge chemical and biological activity databases that all pharmaceutical 
companies now possess, and to make optimal use of these databases [10]. 
2.2 CADD applications in drug discovery and development 
There are several key areas where CADD supports in designing an effective drug. 
Virtual High Throughput Screening (vHTS). vHTS is a method for searching new 
lead molecules to develop into a promising drug for the selected disease target. In vHTS, 
small molecules of the drug like compounds stored in the database are screened against the 
protein targets to find which molecules can bind strongly to the target protein [11].They 
are called lead molecules for the particular disease. These lead molecules are then 
extracted from the database for further testing. With the efficient CADD screening tools 
available nowadays time and the expenditure required for finding a promising lead 
molecule is considerably less than traditional methods. 
Sequence Analysis. The insight knowledge about the amino acid sequence of 
protein molecules of various organisms is essential for a design of the successful drug. 
Many sequence analysis tools and algorithms developed by CADD researchers helps in 
finding out the similarity among the species based on the proteomic and genomic 
sequences. This sequence similarity information is useful in assuming the relationships 
among the various organisms involved in the study. 
Homology Modeling. As most of the drug targets are proteins, scrupulous 
knowledge about the three dimensional structure of those protein molecules is essential 
during drug design. Very few 3-D structures of protein molecules are available in realism. 
However 3-D structures of protein molecules can be predicted using CADD techniques. As 
it is proved that many protein molecules have similar amino acid sequences. If a 3-D 
structure of a protein molecule is known, this structure is used to predict the 3-D structure 
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of the protein molecules which have high similarity scores with the matching protein 
molecules. This process is known as homology modeling. Many database like, SWISS 
MODEL [12] repository having predicted 3-D protein structures, are created using CADD 
homology modeling techniques. 
 Similarity Searches. A common activity during drug discovery is the search for 
drug analogues. Starting with an existing promising lead molecule of a drug, chemical 
compounds with similar protein structure (2D or 3D), common amino acid sequences or 
electrostatic properties etc can be searched using the CADD tools from existing proteomic 
and genomic databases. These drug analogues can be further tested to bring an improved 
drug candidate as an alternative for the existing drug. 
Physicochemical Modeling: Drug-receptor interactions occur on atomic scales. The 
physicochemical properties such as hydrophobicity and polarity of the drug and target have 
an intense effect of how candidate drugs bind to protein targets. As the drug and the target 
interactions occur on atomic scales the study of bio chemical and biophysical properties of 
them provide an in depth understanding about these interactions. 
 Drug Optimization: When a promising candidate drug has been found during the 
drug discovery process, then the newly discovered drug has to be optimized to increase its 
affinity and binding towards target protein. This can be carried out by modifying the 
structure of the drug. Alternate templates or scaffolds like the newly discovered drug are 
evaluated in this stage to find out a promising drug for the disease target. The metabolic 
and toxic properties of the candidate drug are optimized to increase the potential of the 
drug. 
 ADMET properties of a drug: The key characteristics for drugs are Absorption, 
Distribution, Metabolism, Excretion, and Toxicity (ADMET). These properties are called 
as the bioavailability and bioactivity of the drug. Most of the candidate drugs fail in 
clinical trials because of the problems of the toxicity and metabolism of the drugs in 
human beings which makes useless the billions of dollars and years of research spent up to 
this phase. Even though these properties should be measured in the lab, they can also be 
predicted in advance using CADD tools which save the years of research and the huge 
money spent for the experiments on the candidate drug  [13,14]. 




Figure II.1:  CADD in drug discovery 
2.3 Classification of CADD 
CADD can be classified into two general categories: structure-based and ligand-based 
(Figure II.2).   
2.3.1 Ligand-based drug design (LBDD) 
   Ligand-based drug design, or indirect drug design, relies on knowledge of other 
known active molecules with the potential against biological targets of interest [15]. 
Pharmacophore models are derived from these known molecules to define the necessary 
structural characteristics to enable binding to the biological target[16]. Alternatively, in 
quantitative structure-activity relationship (QSAR), we derive the correlation between the 
calculated molecular properties of a compound and their experimentally determined 
biological activity [17]. These predicated QSAR correlations may in turn be used to predict 
the activity of novel analogs [18]. 
2.3.2  Structure-based drug discovery (SBDD) 
 If the three-dimensional structure of a disease-related drug target is known, the most 
commonly used CADD techniques are structure-based. In SBDD the therapeutics are 
designed based on the knowledge of the target structure. Two commonly used methods in 
SBDD are molecular docking approaches and de novo ligand (antagonists, agonists, 
inhibitors, etc. of a target) design. Molecular dynamics (MD) simulations are frequently 
used in SBDD to give insights into not only how ligands bind with target proteins but also 
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the pathways of interaction and to account for target flexibility. This is especially 
important when drug targets are membrane proteins where membrane permeability is 
considered to be important for drugs to be useful [19, 20]. 
 
Figure II.2: Flow chart of CADD processes 
A biomolecular system can be simulated using molecular mechanics (MM), QM, or a 
hybrid method (QM/MM), depending on the research problem to be answered. 
2.4 Molecular mechanics 
  MM is commonly applied in large systems to calculate molecular structures and 
relative potential energies of a molecular conformation or atom arrangement [21-23]. The 
electrons in the studied system are not explicitly considered, but instead each atom – 
specifically, the atomic nucleus and the associated electrons – is treated as a single particle. 
The exclusion of electrons in MM is justified on the basis of Born–Oppenheimer 
approximation [24], which states that electronic and nuclear motions can be uncoupled from each 
other and considered separately. Energy differences between conformations are significant in such 
calculations, rather than absolute values of potential energies. 
MM can simply be viewed as a ball-and-spring model of atoms and molecules with 
classical forces between them [25]. Such forces are accounted by potential energy 
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functions with respect to such structural features as bond length, bond angles, and torsional 
angles. Potential energy functions are equipped with parameters designed to reproduce 
experimental properties [22]. The MM or rather the total potential energy of a molecule is 
described as the sum of bond-stretching energy (Estr), bond angle-bending energy (Ebend), 
torsion energy (Etor), and energy of interactions among unbound atoms (Enb). Energy 
contributions of the latter constitute van der Waals and electrostatic interactions: 
Eto t= Estr+ Ebend+ Etor+ Evdw+ Eelec                                                                                                                   (1) 
Etot = ∑ 𝐾𝑟𝑏𝑜𝑛𝑑𝑠 (𝑟 − 𝑟𝑒𝑞 )
2
+ ∑ 𝐾⍬𝑎𝑛𝑔𝑙𝑒𝑠 (⍬ − ⍬𝑒𝑞 )
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Where Etot is total potential energy, stretch terms refer to Estr, bend terms refer to 
bond angle-bending energy Ebend, torsional terms refer to Etor or twisting energy, and 
unbound interactions are van der Waals forces and electrostatic forces between atoms that 
are not chemically bonded. Energy contributions from special treatment of hydrogen 
bonding and stretch–bend coupling interactions may also be seen in MM. 
2.5 Quantum mechanics  
The QM method treats molecules as collections of nuclei and electrons without any 
reference to “chemical bonds”. QM is important in understanding the behavior of systems 
at the atomic level. QM methods apply the laws of QM to approximate the wave function 
and to solve the Schrödinger equation [21, 26]. The solution to the Schrödinger equation is 
in terms of the motions of electrons, which in turn lead directly to molecular structure and 
energy among other observables, as well as to information about bonding. However, the 
Schrödinger equation cannot actually be solved for any but a one-electron system (the 
hydrogen atom), and approximations need to be made. According to QM, an electron 
bound to an atom cannot possess any arbitrary energy or occupy any position in space. 
These characteristics can determined by solving the time-independent Schrödinger 
equation: [27,28] . 
  H=T+V                                                                                                                              (3)                                                                                 
Where H is the Hamiltonian operator (sum of kinetic energy), T the potential energy, and 
















)𝑖 ] + ∑ ∑ (
𝑒𝑖𝑒𝑗
𝑟𝑖𝑗
)<𝑗𝑖                                                 (4) 
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QM methods include ab initio [29] density functional theory (DFT) [30-32] and semi 
empirical calculations [33-35]. For more accurate QM calculations, electron correlation 
methods, namely, CCSDT and MP2, etc, are necessary [31]. They also help to identify the 
activated complex when applied to reacting chemical species and therefore in the 
identification of a reaction pathway. Since the Schrödinger equation cannot be solved for 
complex molecular systems, semi empirical ab initio DFT methods were developed to 
approximate the precise QM solution to the problem [21, 31, 36].QM models are the most 
accurate, but also the most expensive methods in terms of time and computational 
resources, and are thus applied on small systems. 
Density functional theory  
Density functional theory (DFT) is presently the most successful quantum 
mechanical modeling method used in physics and chemistry to compute the electronic 
structure (principally the ground state) of many-body systems, in particular atoms, 
molecules, and the condensed phases. In chemistry, DFT is used to predict a variety of 
molecular properties, such as molecular structures, vibrational frequencies, atomization 
and ionization energies, electric and magnetic properties, reaction paths, etc. The modern 
DFT calculations are based on two Hohenberg and Kohn theorems, which proves that the 
electronic energy of a molecule in a ground state could be determined completely by 
electron density ρ(r) [37]. The electron density ρ(r) can be defined as in Equation (5), 
where r is spatial variable of electrons and s is the spin variable of electrons. 
ρ(r) = N ∑ …𝑠1 ∑ ∫ 𝑑𝑟2  …𝑠𝑁 ∫ 𝑟𝑁 |Ѱ(𝑟1 , 𝑠1, 𝑟2, 𝑠 … . . 𝑟𝑁, 𝑠𝑁  )|
2 ∫ ρ(r)𝑑𝑟                               (5) 
The Kohn-Sham (KS) theories are the most common implementation of DFT, 
making it widely used. The KS equations are analogous to the Hartree-Fock equations. In 
the KS model, non-interacting electrons moving in an effective potential is introduced to 
solve the problem of interacting electrons of many-body moving in a static external 
potential. The most popular DFT method is the Becke3-Lee-Yand-Parr (B3LYP) hybrid 
functional, and was also used for the calculations in this thesis. Generally speaking, DFT is 
not a CADD method; however, it is involved in application in CADD to predict molecular 
properties. 
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3. Quantitative structure-activity relationships (QSAR) 
3.1  Introduction 
Quantitative structure – activity relationship (QSAR) modeling pertains to the 
construction of predictive models of biological activities as a function of structural and 
molecular information of a compound library. The concept of QSAR has typically been 
used for drug discovery and development and has gained wide application for correlating 
molecular information with not only biological activities but also with other 
physicochemical properties, which has therefore been termed quantitative structure – 
property relationship (QSPR). QSAR is widely accepted predictive and diagnostic process 
used for finding associations between chemical structures and biological activity. QSAR 
appeared and evolved in trying to respond to the need and desire of the specialist chemist 
to predict the biological response [38]. It found its way into the practice of agro chemistry, 
pharmaceutical chemistry, and eventually most facets of chemistry [39]. 
QSAR is the final result of computational processes that start with a suitable 
description of molecular structure and ends with some inference, hypothesis, and 
predictions on the behavior of molecules in environmental, physicochemical and biological 
system under analysis [40]. The final outputs of QSAR computations are set of 
mathematical equations relating chemical structure to biological activity [41-
43].Multivariate QSAR analysis employs all the molecular descriptors from various 
representations of a molecule (1D, 2D and 3D representation) to compute a model, in a 
search for the best descriptors valid for the property in analysis. QSAR’s general 
mathematical form is represented by the following equation. 
QSAR models are not only used for the prediction of properties but are also helpful 
in selection of alternative mechanism of action, determination of useful structural 
characteristics, projecting new design methodologies and help in proposing new 
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3.2  History of QSAR 
Crum-Brown and Fraser expressed the suggestion that the physiological action of a 
substance was a function of its chemical composition. Later, in 1893, Richet showed that 
the cytotoxicities of a dissimilar set of uncomplicated organic compounds were inversely 
related to their corresponding water solubility. After that, Meyer and Overton 
independently recommended that the narcotic action of a group of organic molecules 
correlated with their olive oil/water partition coefficients. The extensive work of Albert, 
and Bell and Roblin established the importance of ionization of bases and weak acids in 
bacteriostatic activity. 
 In the physical organic border, great progress was being made in the clarification 
of substituent effects on organic reactions, led by the influential job of Hammett. Taft 
invented a way for separating polar, steric, and resonance effects and introducing the first 
steric parameter, ES. 
The contributions of Hammett and Taft together laid the mechanistic source for the 
progress of the QSAR model by Hansch and Fujita. In 1962 Hansch et al [44] published 
their bright study on the structure-activity relationships of plant growth regulators and their 
dependency on Hammett constants and hydrophobicity. A Linear Free Energy 
Relationships (LFER) related model published by Fujita et al. and Hansch et al. [45], 
considered to be the official beginning for QSAR. 
Their fragment and additive group contribution idea added two things: the use of 
calculated properties to correlate with biological activities and the detection that multiple 
properties may influence the biological activity. For this purpose, they implemented the 
use of the computer to fit QSAR equations. 
The socalled Hansch equation [46] was developed to correlate physicochemical properties 
(descriptors) with biological activities is given in a general form by: 
Log1/C = a(logP)2 + b(logP) + c ϭ +..............K                                             ( 6) 
 Where C is the molar concentration that produces the biological effect; P is the 
octanol/water partition coefficient and ϭ is the electronic Hammett constant. 
Besides the Hansch approach, other methodologies were also developed to deal with 
structure- activity questions. The Free-Wilson approach [47] addresses structure-activity 
studies in a congeneric series in which the contribution of each structural feature was a 
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parameter of interest. These parameters, also called indicator variables, codify the presence 
or absence of particular structural feature. They are assigned the binary values of 1 and 0, 
accordingly. 
3.3 Tools and Techniques of QSAR 
3.3.1  Biological Parameters 
 In QSAR analysis, it is imperative that the biological data be both accurate and 
precise to develop a meaningful model. It must be realized that any resulting QSAR model 
that is developed is only as valid statistically as the data that led to its development. The 
equilibrium constants and rate constants that are used extensively in physical organic 
chemistry and medicinal chemistry are related to free energy values ΔG. Thus for use in 
QSAR, standard biological equilibrium constants such as Ki or Km should be used in 
QSAR studies.  
Likewise only standard rate constants should be deemed appropriate for a QSAR 
analysis. Percentage activities (e.g., % inhibition of growth at certain concentrations) are 
not appropriate biological endpoints because of the nonlinear characteristic of dose 
response relationships. These types of endpoints may be transformed to equi-effective 
molar doses. 
Only equilibrium and rate constants pass muster in terms of the free-energy 
relationships or influence on QSAR studies. Biological data are usually expressed on a 
logarithmic scale because of the linear relationship between response and log dose in the 
mid-region of the log dose-response curve. Inverse logarithms for activity (log 1/C) are 
used so that higher values are obtained for more effective analogs. Various types of 
biological data have been used in QSAR analysis. A few common endpoints are outlined in 
(Table II.1). 
Biological data should pertain to an aspect of biological/biochemical function that 
can be measured. The events could be occurring in enzymes, isolated or bound receptors, 
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Table II.1: Types of biological data utilized in QSAR analysis 
Source of Activity Biological Parameters 
1. Isolated receptors 









2. Cellular systems  
Inhibition constants  
Cross resistance  
in vitro biological data  






3. In vivo systems 
Biocencentration factor  




Log I (Induction) 
rates Log T ((total clearance) 
 
 
3.3.2  Molecular Descriptors 
Molecular descriptors can be defined as the essential information of a molecule in 
terms of its physicochemical properties such as constitutional, electronic,  hydrophobic, 
lipophilicity,  steric, quantum chemical, and topological descriptors. 
3.3.2.1  Constitutional descriptors:  
Constitutional descriptors capture properties of the molecules that are related to 
elements constituting its structure. These descriptors are fast and easy to compute. 
Examples of constitutional descriptors include molecular weight, total number of atoms in 
the molecule and number of atoms of different identity. Also, a number of properties 
relating to bonds are used including total numbers of single, double, triple or aromatic type 
bonds as well as number of aromatic rings [49]. 
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3.3.2.2  Electrostatic and Quantum-Chemical Descriptors 
Electrostatic descriptors capture information on electronic nature of the molecule. 
These include descriptors containing information on atomic net and partial charges 
[50].Descriptors for highest negative and positive charges are also informative, as well as 
molecular polarizability. Partial negatively or positively charged solvent-accessible atomic 
surface areas have also been used as informative electrostatic descriptors for modeling 
intermolecular hydrogen bonding. Energies of highest occupied and lowest unoccupied 
molecular orbital from useful quantum chemical descriptors as do the derivative quantities 
such as absolute hardness [51]. 
3.3.2.3 Topological descriptors:  
The topological descriptors treat the structure of the compound as a graph, with 
atoms as vertices and covalent bonds as edges. Based on this approach, many indices 
quantifying molecular connectivity were defined starting with Wiener index , which counts 
the total number of bonds in shortest paths between all pairs of non-hydrogen atoms. Other 
topological descriptors include Randic indices x , defined as sum of geometric averages of 
edge degrees of atoms within paths of given lengths,  Balaban’s J index  and Shultz index 
.Information about valence electrons can be included in topological descriptors e.g. Kier 
and Hall indices xv or Galvez topological charge indices [49]. 
3.3.2.4 Steric descriptors: 
Steric descriptors describe size and shape of a molecule. Molecular volume (a sum 
of the van der Waals volumes), molecular surface area or molar refractivity, as a measure 
of the size of a molecule, are commonly used in QSAR studies.    
3.3.2.5  Hydrophobicity descriptors:   
Hydrophobicity descriptor is an important group of descriptors that are widely used 
in drug design and discovery as they can be applied to modeling both pharmacodynamic 
(receptor binding) and pharmacokinetic properties (e.g. the uptake and distribution of a 
xenobiotic relying on partitioning through biological membranes). Partition coefficient (log 
P), distribution coefficient (log D) and aqueous solubility (log S) are important 
hydrophobicity/hydrophilicity descriptors [52]. 
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3.3.3 Statistical methods 
Statistical methods used in QSAR analysis Statistical methods are an essential 
component of QSAR work. They help to build models, estimate a model's predictive 
abilities, and find relationships and correlations among variables and activities. A suitable 
statistical method coupled with a variable selection method allows analysis of this data in 
order to establish a QSAR model with the subset of descriptors that are most statistically 
significant in determining the biological activity. The statistical method can be broadly 
divided in to two: linear and non-linear method. In statistics a correlation is established 
between dependent variables (biological activity) and independent variables 
(physiochemical properties or molecular descriptor). The liner method fits a line between 
the selected descriptor and activity as compared to non-linear method which fit a curved 
between the selected descriptor and activity. 
The statistical method to build QSAR model is decided based on the type of 
biological activity data. Following are commonly used statistical methods 1. Principal 
component analysis (PCA), Cluster analysis (CA), Simple liner regression (SLR) , 
Multiple liner regression (MLR). Stepwise multiple liner regression (MLR ), Principle 
component regression (PCR) ,Continuum Regression (CR ),Partial least squares (PLS) 
,Genetic function approximation (GFA) ,Genetic partial least squares (GPLS) ,Logistic 
regression  (LR) , K-Nearest Neighbors classification (KNN) ,Neural Network(NN) , 
Discriminant analysis (DA) , Decision Trees (DT), Canonical Correlation (CC) [53]. 
3.3.4  Multiple linear regressions (MLR)  
      MLR is a mathematical method used to find a linear relationship between the observed 
response and a number of independent variables (descriptors) as follows: 
𝑦𝑖 = 𝛽0 + 𝛽1𝑥𝑖1 + 𝛽2𝑥𝑖2 + ....+ 𝛽𝑝𝑥𝑖𝑝 + 𝜀𝑖                  𝑖 = 1,2,… , 𝑛                                     (7) 
Where 𝑦𝑖 is the observed response, 𝑥𝑖1, 𝑥𝑖2,…, 𝑥𝑖𝑝 are the independent variables for the ith 
sample, 𝑝 is the number of variables, 𝑛 is the number of samples and 𝜀𝑖 is the error of 
prediction. By estimating the parameters 𝛽0, 𝛽1, 𝛽2,…, 𝛽𝑝 the equation of the  
Linear model is: 
Yî = 𝑏0 + 𝑏1𝑥𝑖1 + 𝑏2𝑥𝑖2 + ....+ 𝑏𝑝𝑥𝑖𝑝                                                                                                                                                   (8) 
Where 𝑏0, 𝑏1, 𝑏2..... 𝑏𝑝 are the estimates of the previous parameters and Yî is the predicted 
value of the model. 
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MLR is based on the Orthogonal Least Square (OLS) algorithm that minimizes the sum of 
squares of the error between the predicted and the observed values Σ(𝑦 −Ŷ)2 . 
The vector of predicted valuesŶ  is obtained as following: 
 Ŷ= b X                                                                                                                                                  (9)              
Where b is the vector of estimated parameters 𝑏0, 𝑏1, 𝑏2,…, 𝑏𝑝 calculated as: 
b = (X′X) −1X′Y                                                                                                                         (10) 
Where X and Y are the matrix of descriptors and the vector of experimental responses, 
respectively. 
MLR modeling is based on the assumption that the errors are a normally distributed 
random variable with constant variance. The obtained model is optimal when the 
regression estimators are unbiased, efficient, and consistent with a bias and variance 
approaching zero when the number of samples tends to the infinity. 
The disadvantage of this method is that collinearity between the descriptors highly 
affects the reliability of the regression coefficient estimates. Thus, reducing the number of 
included variables by removing those with insignificant coefficients can reduce the risk of 
multi-collinearity and contribute to enhance the reliability of predictions [54]. 
3.4  Validation of QSAR Models 
After the model equation is obtained, moreover the stability and the goodness of fit of the 
model, it is also significant to estimate the power and the validity of the model before 
using it to predict the biological activity. Validity is to establish the reliability and 
significance of the method for a particular use. Therefore, validation of a QSAR model 
must be done. There are two validation methods used for a QSAR model: internal and 
external validation techniques to establish the confidence and strength of the model. In 
general, QSAR modeling involves a systematic process with multiple steps. These include 
dataset preparation, molecular descriptors selection and generation, mathematical or 
statistical models derivation, model training and validation using a training dataset and 
model testing on a testing dataset.  
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3.4.1 Internal Validation: 
3.4.1.1 Least Squares Fit 
The most common internal method of validating the model is least squares fitting. 
This method of validation is similar to linear regression and is the R2 (squared correlation 
coefficient) for the comparison between the predicted and experimental activities. An 
improved method of determining R2 is the robust straight line fit, where data points are 
away from the central data points (essentially data points a specified standard deviation 
away from the model) are given less weight when calculating the R2. An alternative to this 
method is the removal of outliers (compounds from the training set) from the dataset in an 
attempt to optimize the QSAR model and is only valid if strict statistical rules are 
followed. The difference between the R2 and R2adj value is less than 0.3 indicates that the 
number of descriptors involved in the QSAR model is acceptable. The number of 






                                                                                (11) 
 
3.4.1.2 Fit of the Model 
Fit of the QSAR models can be determined by the methods of chi-squared ϰ2and 
root-mean squared error (RMSE). These methods are used to decide if the model possesses 
the predictive quality reflected in the R2. The use of RMSE shows the error between the 
mean of the experimental values and predicted activities. The chi squared value exhibits 
the difference between the experimental and predicted bioactivities: 
ϰ2  = ∑𝐢=𝟏
𝐧 (
 ( Yi  −Yî)
2
Yî
)                                                                                        (12)  
RMSE=√(∑𝐢=𝟏
𝐧 ( Yi  −Ym̂)
2
n−1
                                                                                                              (13) 
Where, y and ŷ are the experimental and predicted bioactivity for an individual 
compound in the training set, ym is the mean of the experimental bioactivities, and n is the 
number of molecules in the set of data being examined. Large chi-square or RMSE values 
reflect the model’s poor ability to accurately predict the bioactivities even the model is 
having large R2 value (≥0.7). For good predictive model the chi and RMSE values should 
be low (<0.5 and <0.3, respectively). 
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However, excellent values of R2,  ϰ2 and RMSE are not sufficient indicators of 
model validity. Thus, alternative parameters must be provided to indicate the predictive 
ability of models. In principle, two reasonable approaches of validation can be envisaged 
one based on prediction and the other based on the fit of the predictor variables to 
rearranged response variables. 
3.4.1.3 Cross-validation 
Cross-validation is one of the most extensively used methods for internal validation. 
This involves a leave-one-out (calculation of q2 LOO) cross-validation [57]. For 
calculating RCV
2 (Q2) , each sample in the training set was eliminated once and the activity 
of the eliminated sample was predicted by using the model developed by the remaining 
samples. LOO-RCV
2 (Q2) calculated according to the below formula: 
RCV
2 (Q2) = 1 −
∑(Ypred−Yobs)2
∑(Ypred−Ymean)2
> 0.5                                                                                                                 (14)                                
In Eq. (14), Ypread and Yobs indicate predicted and observed activity values 
accordingly and Ymean signify mean activity value. A model is considered acceptable 
when the value of RCV
2 (Q2) exceeds 0.5.  
The following statistical parameters were calculated to test the validation of 
developed models; PRESS, SSY, SPRESS  and R2adj. The following equations are used to 
calculate above parameters. 
PRESS=Ʃ (Yobs- Ypred)2                                                                                                                                                 (15) 
SSY=Ʃ (Yobs- Y mean)2                                                                                                                                                      (16) 
SPRESS= √PRESS\n                                                                                                         (17) 
R2adj= 1- (r
2) [n-1/n-p-1]                                                                                                    (18) 
PE=0.6745 (1-r2) / √𝑛                                                                                                        (19) 
PRESS is used for predicting sum of squares. To validate a regression model with 
respect to predictability, PRESS is utilized. The deviation of Yobs from the actual Y value 
is called the prediction error. The sum of the squared prediction errors is known as PRESS 
value.  The lesser PRESS value shows higher predictability of the model. If PRESS value 
is lesser than SSY then predictability of model is better than chance and it is statistically 
significant. 
Chapter II                                                        Computational methods in drug discovery                                            
40 
 
3.4.2 External validation 
According to Tropsha et al. [58], for considering the validity of the developed 
models, in addition to the internal validation, the models should be externally validated 
using the test set compounds. According to their study, the following criteria could be 
considered as of acceptable predictability: 
Rpred
2 = 1 −
∑(Ypred−Yobs)2
∑(Ypred−Ymean(train))2
> 0.6                                                                        (20)                                        
Where Rpred
2  is squared correlation coefficient between the experimental and predicted 
biological activities of dataset compounds (training and test sets). 
Ypred and Yobs indicate predicted and observed activity values for the test set and 








 < 0.1                                                                                      (21)                                                           
|R0
2 − R′0
2| < 0.3                                                                                                                              (22) 
Where R2 is determination coefficient between the experimental and predicted pIC50 
values of test set compounds with intercept.R0
2  and  R′0
2 are determination coefficients of 
predicted versus experimental and experimental versus predicted biological activity values 
in which their regression line must pass through the origin, respectively. 
0.85≤ K ≤1.15           or          0.85≤ K' ≤1.15                                                                   (23)                                         
The slope of regression line through the origin which mentioned in the above was indicated 
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4. Molecular Docking 
4.1 Introduction 
Docking is the computational determination of binding affinity between a protein 
structure and a ligand .This method involves proficient sampling of all possible poses of 
the ligand in the binding pocket of the target protein to ease optimal binding geometry, as 
measured by the defined scoring functions [59, 60]. 
Molecular docking protocols can also be defined as a blend of a search algorithm 
and a scoring function. [61-63]. Many scoring functions and algorithms are currently 
available. The search algorithm is supposed to provide support and freedom to the protein- 
ligand coordination to enable accurately and sufficient sampling, including the binding 
modes. Logically, the search algorithm is supposed to have good speed and effectiveness, 
while the scoring function must be able to analyze physicochemical properties of 
molecules and thermodynamics of interaction. 
A reliable docking algorithm should exhaustively search all possible binding modes 
between the ligand and target; however, this is impractical because of the large size of the 
search space. Therefore, constraints, restraints, and approximations are applied to reduce 
the dimensionality of the problem in an attempt to locate the global minima as efficiently 
as possible. Since large conformational space is available to protein structures, partial 
flexibility (side chain) has recently been incorporated into some docking algorithms, e.g., 
GLIDE, GOLD, AUTODOCK, FlexX , etc. Genetic algorithms (AUTODOCK, GOLD) 
and Monte Carlo simulated annealing algorithms (GLIDE) are widely used.  
The genetic algorithm is an iterative process that sustains a population of 
individuals that are candidates of the solutions to the problem being elucidated. However, 
simulated annealing is an iterative procedure that constantly apprises one candidate 
solution until it reaches a termination condition [64]. 
4.2 Search Algorithms 
Docking applications can be classified by their search algorithms, which are 
defined by a set of rules and parameters applied to predict the conformations. When we 
consider the flexibility of the ligand and/or the receptor docking algorithms can be 
classified in two large groups: rigid-body and flexible docking. Rigid-body docking 
method does not take into account the flexibility of neither ligand nor receptor, limiting the 
specificity and accuracy of results, considering essentially geometrical complementarities 
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between two molecules. Rigid-body docking simulation even not taking into account 
flexibility is capable of identifying ligand binding sites for several different proteins. 
Illustrate structures where rigid-body docking simulations were able to predict the correct 
position of ligand, when compared to crystallographic structures [65-70]. All rigid-body 
docking simulations were carried out with ZDOCK [71], and superposition of the best 
results, evaluated using empirical scoring functions, against crystallographic structures 
generated RMSD lower than 1.0 Å. This RMSD is calculated between two sets of atomic 
coordinates, in this case, one for the crystallographic structure (xc,yc,zc) and another for the 
atomic coordinates obtained from the docking simulations (xd,yd,zd), the summation is 
taken over all N atoms being compared, the equation is as follows: 
RMSD = √ 
1
𝑁
∑ (𝑥𝑐𝑖 − 𝑥𝑑𝑖)2 + (𝑦𝑐𝑖 − 𝑦𝑑𝑖 )2 + (𝑧𝑐𝑖 − 𝑧𝑑𝑖)2
𝑁
𝑖=1                                            (24) 
In docking simulations we expect that the best results generate RMSD values below 
1.5 Å, when compared to crystallographic structures. 
Rigid-body docking simulation has been employed for virtual-screening 
initiatives, this method has been used as the fastest way to perform an initial screening of a 
small molecule database. It has a relatively high accuracy, when compared against 
crystallographic structures. This accuracy is even higher if we introduced an analysis of the 
best results using an empirical scoring function for the best results obtained using rigid-
body docking simulations. Usually, flexible docking or/and scoring functions have been 
used for applying a more specific refinement and lead optimization after initial rigid body 
docking procedure, since these methods demand for computational power and CPU time. 
Flexible docking methods can consider several possible conformations of ligand or 
receptor, as well as for both molecules at the same time, at a higher computational time 
cost. Docking applications usually make use of one or more of the following methods: fast 
shape matching (SM) , incremental construction (IC) , Monte Carlo simulations (MC), 
distance geometry (DG), evolutionary programming (EP), genetic algorithms (GA), tabu 
search (TS)  and simulated annealing (SA) [72]. 
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4.3 Scoring functions  
Scoring function is the most important component in structure based drug design 
for evaluating the efficacy of ligands binding to their target proteins [73] .The docked 
poses are ranked and evaluated using scoring functions that approximate the binding free 
energy of a ligand to a receptor, which is a crucial step to differentiate correct poses from 
incorrect ones. The scoring functions make various assumptions and simplification in the 
evaluation of binding free energy for modeled complexes and do not fully consider some 
of the physical phenomena that are important for molecular recognition, i.e, entropic 
effects, as the scoring functions must be calculated rapidly during the docking run. 
Normally the scoring functions are expressed as a sum of separate terms that describe the 
various contributions to ligand binding. A large number of scoring functions are available, 
such as force filed-based, empirical and knowledge-based scoring functions, which differ 
in which terms that are included in the expression of the binding free energy. Terms 
expressing no bonded interactions, including Van der Vaals interactions and electrostatic 
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Amino-pyrimidineis one of the most important and well-known heterocycles and  
constitute a common structural motif in alarge number of naturally occurring and 
biologically active compounds.In fact amino-pyrimidines with substituent's either at or at 
4th-position are present in many drug-like scaffolds with great chemotherapeutic potential. 
They are associated with antifungal, pesticideand enzyme inhibitory activities. They inhibit 
several kinases, such as Bcr-Abl kinase, rho-associated protein kinase and serine/threonine 
protein kinase PKnB[1,2]. 
 
Figure III.1: 2D Structure of amino-pyrimidine 
 
The discovery and development of new anti-TB therapeutics is widely recognized as 
one of the major global health emergencies, yet it is also a major pharmaceutical challenge. 
A theoretical technique such as quantum chemical descriptors have been extensively used 
in Quantitative Structure-Activity Relationship (QSAR) [3,4] to predict the physiological 
and biological properties of compounds understudy. Whether these compounds amino-
pyrimidine derivatives provide structural precedence and may lead to the generation of 
novel anti-TB therapeutics. 
The process of drug development is time-consuming and cost-intensive. Several 
years are required for led identification, optimization,in vitro and in vivotesting before 
starting the first clinical trials. Drug discovery activities are producing ever-larger volumes 
of complex data that carry significant levels of uncertainty; multi-parameter optimization 
methods enable this data to be better utilized to quickly target compounds with a good 
balance of properties, but they all have their strengths and weaknesses [5].Therefore, we 
can use the MPO methods to predict the best balance of properties, among these methods 
we carry out rules of thumb and calculated metrics. 
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Rules of thumb are the most common approach used to consider the quality of 
compounds relative to criteria beyond potency that provides guidelines regarding desirable 
compound characteristics. Several rules have been proposed; the most commonly used are 
Lipinski and Veber rules [6, 7]. On the other hand, calculated metrics aim to combine the 
potency with other parameters into a single metric which may be monitored during 
optimization. The earliest and most commonly applied metrics are the Ligand Efficiency 
(LE) and the Lipophilic Efficiency (LipE) [5]. 
2. Materials and methods 
2.1 Data Set 
In this study, we selected 29 amino-pyrimidine derivatives as Mycobacterium 
tuberculosis PknB inhibitors were taken from the literature [2, 8, 9]. The activities are 
reported as pIC50 (pIC50=-log (IC50)), where IC50 is the molar concentration of the 
compound required for 50% inhibition of inhibitory activity.The compounds and their 
corresponding biological activity pIC50values are shown in (Figure III.2)   and (Table 
III.1). 
The data set was divided into the two subsets, training set of 22 compounds and test 
set of 7 compounds. The test set compounds were selected manually considering the 
distribution of biological data and structural diversity. Training set was used to build a 
regression model, and the test set was used to evaluate the predictive ability of the model 
obtained. 
2.2 Molecular Descriptors 
In the first part of this work,the twenty-nine molecules were pre-optimized 
using the Molecular Mechanics Force Field (MM+)method included in HyperChem 
version 8.08packag [10]. The resultant minimized structures were further refined using the 
semi empirical PM3 Hamiltonian as implemented also in HyperChem. The gradient norm 
limit of 0.01 kcal/Å was chosen for the geometry optimization. 
In the second part, the series of the amino- pyrimidine derivatives was re-optimised 
by the density functional theory DFT/B3LYP[11-13] at the 6-311G(d,p) basis set of level, 
by using Gaussian 09 software [14].Further, the regression analysis was performed using 
the SPSS version 21 for Windows [15]. 
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The QSAR properties module from HyperChem (8.08) was used to calculate: molar 
polarizability(Pol), the molar refractivity (MR), partition coefficient octanol/water(log P), 
molar volume (MV), hydratation energy(HE),Surface area grid (SAG) and molar weight 
(MW).Molinspiration[16] web based software was used to obtain parameter such as PSA, 
nrotb. The calculated results have been reported in the present work. 
The Quantum Chemical descriptors: dipole moment (DM), HOMO-LUMO energy 
gap (∆E), total energy (ET) and atomic net charges (Natural bond orbital charges NBO) 
(qN1, qC2, qN3, qC5 and qN6) were computed using Gaussian 09 software.The 2D 
structures of amino- pyrimidine derivatives were drawn using  MarvinSketch 
17.1.2software[17] (Figure III.1). 
2.3 Model validation 
The multiple linear regression statistic technique is used to study the relation 
between one dependent variable and several independent variables. It is a mathematic 
technique that minimizes differences between actual and predicted values.  
Statistical properties of the proposed equation such as the squared correlation 
coefficient (R2>0.6) which is a relative measure of quality of fit. Standard error of estimate 
(SEE < 0.3) representing absolute measure of quality of fit, Fischer’s value (F), is the 
Fisher ratio, reflects the ratio of the variance explained by the model and the variance due 
to the error in the regression. High values of the F -test indicate that the model is 
statistically significant by Deardenet al.[18].  
The main objective of a QSAR study is to obtain a model with the highest predictive 
and generalizationabilities. In order to evaluate the predictive power of the QSAR models 
developed, two principals (internal validation and external validation) were performed (see 
chapter II). For the internal validation the leave-one-out cross-validation (RCV
2 (Q2)) was 
used to evaluate the stability and the internal capability of the models in the present paper. 
A highRCV
2 (Q2) value means a high internal predictive power ofa QSAR model and a good 
robustness. Nevertheless, the study of Globarikh [19] indicated that there is no correlation 
between the value of RCV
2 (Q2) for the trainingset and predictive ability of the test set, 
revealing that the RCV
2 (Q2) is still inadequate for a reliable estimate of model's predictive 
power for all new chemicals. 
So, the external validation remains the only way to determine both the 
generalizability and the true predictive power of QSAR models for new chemicals. For this 
reason, the statistical external validation was applied to the models as described by 
Globarikh and Tropsha [19, 20].   
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3. Results and discussion 
3.1 Structure Activity Relationship (SAR)and drug likeness 
In the first step of our studies, we have studied some physico-chemical proprieties of 
twenty nine amino- pyrimidine derivatives by HyperChem software, Molecular weight 
(MW), Molecular volume (MV), Molecular surface (MS), the octanol/water partition 
coefficient (LogP), hydrogen bond acceptor (HBA), hydrogen bond donor (HBD), 
polarizability(Pol), refractivity(MR)and hydratation energy(HE). Polar surface area (PSA), 
number of rotatable bond (NRB) calculated by Molinspiration, ligand efficiency (LE) and 
Lipophilic efficiency (LipE) are the properties studied in the present work. Results are 
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Figure III.2:Structure of amino- pyrimidine derivatives. 
  
These parameters allow ascertaining oral absorption or membrane permeability that 
occurs when the evaluated molecule follows Lipinski’s rule of five. 
(1) There are less than 5 H-bond donors (expressed as the sum of OHs and NHs). 
(2) The molecular weight is under 500 DA. 
(3) The log P is under 5. 
(4) There are less than 10 H-bond acceptors (expressed as the sum of Ns and Os)for an 
ideal oral bioavailability,there are two other descriptors identified by Veber et al : 
(1) Rotatable bonds are under 10.  
(2) Polar surface area is under 140 Å2. 
Veber rules suggest that molecular flexibility and polar surface area (PSA) are important 
determinants of oral bioavailability [7]. 
Computation of molar refractivity was made via the same method as logP, Ghose 
and Crippen presented atomic contributions to the refractivity [21]. 
The solvent-accessible surface bounded molecular volume and van der Waals-
surface-bounded molecular volume calculations are based on a grid method derived by 
Bodor et al [22].using the atomic radii of Gavezzotti [23]. 
The hydration energy is a key factor determining the stability of different molecular 
conformation [24]. 
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Lipophilicity is a property that has a major effect on solubility, absorption, 
distribution, metabolism, and excretion properties as well as pharmacological activity. 
Lipophilicity has been studied and applied as an important drug property for decades. It 
can be quickly measured or calculated. Lipophilicity has been correlated to many other 
properties, such as bioavailability, storage in tissues, permeability, volume of distribution, 
toxicity, plasma protein binding and enzyme receptor binding [25,26]. 
The polarizability of a molecule depends only on its volume; the thermal agitation of 
the non-polar molecules does not have any influence on the appearance of dipole moments 
in these molecules. Furthermore, the polar molecules, the polarizability of the molecule 
does not depend solely on volume but also depends on other factors such as the 
temperature, because of the presence of the permanent dipole [27].The polarizability 
values(Table III.2) are generally proportional to surfaces and of volumes. The decreasing 
order of polarizability for these studied amino-pyrimidines is: 12,8,10,3, 
29,9,4,27,5,28,11,26,6,7,2,25,1,21,22,19,18,14,15,16,22,17,24,13,23. 
The order of polarizability is approximately the same one for volume and surface. This is 
explained by the relation between polarizability and volume, for the relatively non polar 
molecules. 
Molecular weight (MW) is related to the size of the molecule. As molecular size 
increases, a larger cavity must be formed in water in order to solubilize the 
compound.Increasing MW reduces the compound concentration at the surface of the 
intestinal epithelium, thus reducing absorption. Increasing size also impedes passive 
diffusion through the tightly packed aliphatic side chains of the bilayer membrane. All the 
studied compounds of amino-pyrimidine derivatives have a molecular weights less than 
500 Da (rule number 2), so they are likely soluble and easily pass through cell membranes. 
Molecular volume determines transport characteristics of molecules, such as 
intestinal absorption or blood-brain barrier penetration. Volume is therefore often used in 
QSAR studies to model molecular properties and biological activity [28]. 
These compounds have a great variation of distribution volume, in particular compound 
12, which has the volume: 1369.02Å3(Table III.2). 
The most important hydration energy in the absolute value, is that of the compound 6 
(17.6 kcal/mol) and the weakest is that of compound 26 (4.58 kcal/mol) (Table 
III.2).Indeed in the biological environments the polar molecules are surrounded by water 
molecules. 
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The first correspond to the complex with the strongest hydrogen bond. These hydrated 
molecules are dehydrated at least partially before and at the time of their interaction.These 
interactions of weak energy, which we observe in particular between messengers and 
receivers, are generally reversible. 
Compound 12 has nine acceptor sites of proton, and three donor sites. Moreover, 
compounds 25, 26 have six acceptor sites, and one donor site of proton. The first having 
higher value, it has three  more acceptor sites of proton, and two  donor sites(Table 
III.1).This property supports the first compound, not only by fixing on the receiver, but 
also by activating. It is thus about an agonist. It has as a consequence, a better distribution 
in fabrics.  
For good oral bioavailability, the LogP must be greater than zero and less than 3 
(0 <LogP<3). For LogP too high, the drug has low solubility and a LogP too low, the drug 
has difficulty penetrating the lipid membranes[29]. 
Compounds 20, 15 present the lowest coefficient of division (-0.16, -0.12). When the 
coefficient of division is rather low, it has as a consequence for a better gastric tolerance 
and good solubility. In the other hand compounds 16 present the highest value of 3.41, 
which means it has the capacity to the fixation on plasmatic proteins and a good passage 
through the biological membrane.The majority of (LogP) of studied molecules have 
optimal values. 
The number of rotatable bonds (NRB) was defined as any single bond, not in a ring, 
bound to a no terminal heavy (i.e., non-hydrogen) atom. Excluded from the count were 
amide C–N bonds because of their high rotational energy barrier [23].The low number of 
rotatable bonds(reduced flexibility) in the studied series indicates that these ligands upon 
binding to a protein change their conformation only slightly. Rotatable bonds are under 10 
so all the screened compounds were flexible. 
Polar surface area (PSA) is a very useful parameter for prediction of drug transport 
properties. Polar surface area is defined as a sum of surfaces of polar atoms (usually 
oxygens, nitrogens and attached hydrogens) in a molecule. This parameter has been shown 
to correlate very well with the human intestinal absorption,Caco-2 monolayer’s 
permeability and blood-brain barrier penetration[30]. PSA ofamino- pyrimidine derivatives 
were found in the range of 57.18-112.66 and are well below the 140 Å2 belong to the 
compounds with reduced absorption(Table III.1). 
In our case, the Lipinski and Veber rules are validated. Therefore, theoretically, all 
chosen compounds will not have a problem with oral bioavailability. 
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Table III.1: Drug-likeness parameters of amino-Pyrimidine derivatives. 










pIC50 LE LipE 
1 363.47 1.81 7 3 0 8 81.76 7.06 0.366 5.25 
2 375.48 1.99 7 2 0 5 72.97 6.92 0.346 4.93 
3 403.53 2.23 7 3 0 7 81.76 7.14 0.333 4.91 
4 389.50 1.81 7 3 0 6 81.76 7.28 0.351 5.47 
5 390.49 2.45 7 2 0 8 78.97 7.25 0.350 4.80 
6 386.46 0.42 8 4 0 8 10.20 6.46 0.311 6.04 
7 378.48 2.18 7 2 0 9 78.97 7.26 0.363 5.08 
8 419.53 1.93 8 2 0 8 82.20 7.02 0.317 5.09 
9 392.50 2.81 7 2 0 10 78.97 7.04 0.339 4.23 
10 414.51 1.84 8 2 0 6 96.76 7.25 0.327 5.41 
11 388.47 1.53 8 3 0 8 105.55 7.41 0.334 5.88 
12 481.62 0.64 9 3 0 8 115.90 7.40 0.304 6.76 
13 309.35 2.06 8 2 0 4 66.49 6.43 0.391 4.67 
14 334.38 1.18 5 4 0 5 109.59 6.42 0.359 5.24 
15 369.44 -0.12 7 2 0 5 100.64 7.07 0.380 7.19 
16 312.42 3.41 7 3 0 5 78.52 7.08 0.430 3.64 
17 300.41 3.36 6 3 0 7 78.52 6.45 0.410 3.09 
18 320.40 2.84 6 3 0 6 78.52 6.15 0.358 3.31 
19 330.39 2.72 6 3 0 6 78.52 6.66 0.444 3.94 
20 384.46 -0.16 8 3 0 6 112.66 6.41 0.332 6.57 
21 398.48 1.54 8 3 0 7 112.66 6.62 0.331 5.08 
22 316.37 2.39 6 2 0 4 90.29 7.06 0.411 4.78 
23 292.34 1.32 6 2 0 4 79.39 6.69 0.425 5.37 
24 298.39 1.83 6 3 0 5 78.52 6.94 0.441 5.11 
25 360.46 2.30 6 1 0 5 57.18 5.21 0.270 2.91 
26 428.46 3.25 6 1 0 6 57.18 6.28 0.283 3.03 
27 390.49 1.31 7 1 0 6 66.41 5.95 0.287 4.64 
28 385.47 3.15 7 1 0 5 80.97 5.70 0.275 2.55 
29 453.47 2.59 7 1 0 6 80.97 7.40 0.323 4.81 
 
Besides that, we have studied the Ligand efficiency (LE) is a simple metric for 
assessing whether a ligand derives its potency from optimal fit with the target protein or 
simply by virtue of making many contacts. It shows generally a dependency on ligand size. 
Ligand efficiency drops dramatically when the size of the ligand increases.  
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Ligand efficiency is used in drug discovery programs to assist in narrowing focus to 
lead compounds with optimal combinations of physicochemical properties and 
pharmacological properties. It is frequently used to evaluate fragment compounds in 
fragment-based drug discovery [31]. 
Lipophilicity efficiency (LipE) provides as straight forward and meaningful way to 
evaluate the quality of research compounds, linking potency and lipophilicity in an attempt 
to estimate drug-likeness, attempts to maximize the minimally acceptable lipophilicity per 
unit of in vitro potency or more simply, to improve potency, while maintaining low 
lipophilicity [32]. 
Ligand efficiency (LE) and Lipophilicity efficiency (LipE) are defined as follows:  
LE = 1,4pIC50/NH (1) 
Where: NH is the number of heavy atoms. So LE decreases with increasing number of 
heavy atoms [33]. 
LipE = pIC50−logP (2) 
High LE prefers compounds that gain to escape the affinity-biased selection and 
optimization towards larger ligands. The focus should be directed towards the generation 
of compounds that use their atoms most efficiently. As regards LipE, it prefers compounds 
that gain a lot of their affinity through directed interactions, thus making the interaction 
with the receptor more specific. While one can say that LipE describes how efficient a 
Ligand exploits its lipophilicity, no explicit measure of molecular size is used from the 
results obtained in (Table III.1 ) we can say for ligands containing pIC50 >7 we are able to 
penalize compound 8 with lowest LE value (0.317), for ligands containing7>pIC50 >6 we 
can penalize the compound 26  with lowest LE value (0.283) and for compounds 
containing pIC50 <6 we can penalize compounds 25 and 28 with lowest LE values 0.270 
and 0.275 respectively on the other side, Compounds 1,4,6,7,8,10,11,12,14,20,21,23 and 
24 reach a LipE  of 5.25, 5.47, 6.04, 5.08, 5.09, 5.41, 5.88, 6.76,5.24, 6.57, 5.08, 5.37and 
5.11 respectively, which are situated in the suggested range of 5–7, this indicates that these 
compounds were successfully optimized.  
We can see through the results in (Table III.1) that compound 12 had the highest 
LipE value of the data set and was deemed to be the most optimal compound. 
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3.2 Quantitative Structure-Activity Relationships Studies 
In the second step, the several physico- chemical descriptors were used as 
independent variables (Table III.2) and were correlated withbiological activities of amino-
pyrimidine derivatives for the generationof QSAR model by multiple linear regressions 
(MLR) analyzes. The structures of studied compounds are shown in (Figure.III 1).  














1 363.47 676.89 1137.04 41.62 113.02 -8.87 1.81 
2 375.48 666.97 1130.58 42.69 116.35 -7.28 1.99 
3T 403.53 727.93 1234.55 46.36 125.27 -7.95 2.23 
4T 389.50 685.27 1175.67 44.52 120.46 -7.93 1.81 
5 390.49 692.41 1182.78 43.81 118.62 -7.51 2.45 
6 386.46 648.19 1128.08 43.43 118.95 -17.6 0.42 
7 378.48 700.00 1178.93 42.75 115.94 -7.95 2.18 
8 419.53 720.61 1250.68 46.99 127.13 -7.72 1.93 
9 392.50 721.55 1221.92 44.58 120.57 -7.45 2.81 
10 414.51 715.62 1240.43 46.37 125.86 -9.83 1.84 
11 388.47 690.78 1175.96 43.48 118.00 -9.81 1.53 
12 481.62 791.24 1369.02 49.33 138.94 -12.26 0.64 
13 309.35 561.65 917.18 33.33 91.97 -7.37 2.06 
14 334.38 580.68 982.60 36.69 99.66 -11.52 1.18 
15 369.44 604.52 1035.66 36.39 106.69 -9.22 -0.12 
16T 312.42 604.63 996.87 35.34 92.11 -6.44 3.41 
17 300.41 593.65 985.85 34.28 89.52 -6.57 3.36 
18T 320.40 603.62 999.47 36.60 99.85 -9.38 2.84 
19 330.39 617.61 1115.49 37.10 83.04 -7.44 2.72 
20 384.46 645.49 1080.42 37.74 109.99 -12.29 -0.16 
21 398.48 675.55 1141.48 39.58 112.97 -11.81 1.54 
22 316.37 588.60 962.93 35.27 96.82 -13.21 2.39 
23T 292.34 552.48 895.67 32.71 88.34 -9.69 1.32 
24T 298.39 571.88 943.99 33.51 88.70 -6.85 1.83 
25T 360.46 637.86 1092.89 41.92 114.92 -9.00 2.30 
26 428.46 682.82 1173.21 43.48 120.33 -4.58 3.25 
27 390.49 688.88 1173.45 44.39 121.30 -7.30 1.31 
28 385.47 669.46 1153.85 43.77 116.52 -10.49 3.15 
29 453.47 694.49 1209.04 45.33 125.12 -9.85 2.59 
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qN1  qC2 qN3 qC4 qC5  qC6 
1 4.74 -1160.695 0.234 -0.581 0.469 -0.558 0.460 -0.406 0.455 
2 5.71 -1198.813 0.162 -0.593 0.466 -0.585 0.453 -0.399 0.469 
3T 2.58 -1277.461 0.234 -0.588 0.474 -0.592 0.460 -0.396 0.463 
4T 1.74 -1238.144 0.241 -0.593 0.475 -0.592 0.449 -0.394 0.463 
5 2.50 -1258.010 0.239 -0.604 0.476 -0.577 0.454 -0.375 0.591 
6 2.00 -1251.789 0.242 -0.597 0.474 -0.592 0.455 -0.388 0.455 
7 3.72 -1219.888 0.237 -0.597 0.472 -0.542 0.451 -0.378 0.593 
8 2.07 -1352.677 0.240 -0.608 0.475 -0.578 0.453 -0.374 0.591 
9 4.16 -1259.211 0.237 -0.595 0.473 -0.542 0.451 -0.378 0.594 
10 6.11 -1330.400 0.242 -0.592 0.467 -0.593 0.459 -0.391 0.460 
11 5.90 -1252.970 0.247 -0.583 0.465 -0.592 0.464 -0.399 0.456 
12 9.65 -1865.431 0.251 -0.601 0.466 -0.579 0.455 -0.398 0.464 
13 3.94 -1031.279 0.244 -0.557 0.468 -0.570 0.458 -0.336 0.282 
14 1.45 -1100.770 0.052 -0.557 0.464 -0.564 0.458 -0.332 0.279 
15 4.28 -1519.949 0.244 -0.556 0.461 -0.566 0.458 -0.324 0.276 
16T 2.68 -991.024 0.251 -0.613 0.648 -0.611 0.464 -0.382 0.288 
17 2.83 -952.905 0.252 -0.612 0.645 -0.613 0.464 -0.380 0.290 
18T 2.84 -1026.712 0.255 -0.612 0.645 -0.611 0.464 -0.380 0.290 
19 2.94 -912.333 0.250 -0.617 0.645 -0.612 0.464 -0.383 0.289 
20 2.30 -1575.339 0.253 -0.547 0.460 -0.536 0.460 -0.338 0.279 
21 9.70 -1614.662 0.244 -0.550 0.462 -0.532 0.456 -0.337 0.280 
22 8.99 -1024.280 0.052 -0.556 0.459 -0.557 0.460 -0.349 0.292 
23T 8.39 -948.055 0.245 -0.548 0.453 -0.562 0.454 -0.341 0.291 
24T 2.95 -951.687 0.247 -0.620 0.644 -0.612 0.464 -0.382 0.288 
25T 3.60 -1143.499 0.229 -0.428 0.362 -0.424 0.462 -0.237 0.464 
26 7.75 -1480.623 0.226 -0.576 0.471 -0.549 0.451 -0.387 0.463 
27 5.34 -1258.055 0.230 -0.585 0.466 -0.588 0.447 -0.390 0.465 
28 5.61 -1235.762 0.241 -0.579 0.470 -0.598 0.454 -0.384 0.463 
29 8.48 -1572.897 0.233 -0.580 0.467 -0.578 0.448 -0.400 0.472 
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3.2.1 Internal validation 
The MLR model was developed by applying the selected molecular descriptors (Table III.2) 
to the “active compounds” of the training data (22 compounds).  
 Pearson’s correlation matrix has been performed on all descriptors by using SPSS statistics 
21 Software. The analysis of the matrix revealed ten descriptors for the development of MLR 
model. 
The correlation between the biological activities and descriptors expressed by the following 
relation: 
𝑝𝐼𝐶50 = −50.585 − 0.002𝑆𝐴𝐺 + 0.065𝐻𝐸 − 0.260 𝐿𝑜𝑔 𝑃 + 0.128𝑀𝐷 +  0.001𝐸𝑇 
−49.366𝑞𝑁1 − 11.471𝑞𝐶2 + 14.051𝑞𝑁3 + 107.556𝑞𝐶4 + 11.553𝑞𝐶5      (3)        
 
N= 22          R=0.986         SEE= 0.110            F = 39.341           RMSE= 0.078   Q = 8.963 
 
Where N is the number of compounds (training set). 
 
The model shows a good correlation coefficient (R) of 0.986 between descriptors (Log P, 
SAG, HE, MD, ET, qN1, qC2, qN3, qC4andqC5). 
In this model the values of qC4, qN3, qC5 , ET,MD and HE suggest that the activity increases with 
the increase of these descriptors values, on the other hand the activity decreases with increasing the 
values of qN1, qC2, log P and SAG.  Since they have a negative value in this equation (3). 
Low value of standard error of estimate (<0.3) indicates the accuracy of the statistical fit. All 
the values of the t-statistic are significant which confirms the significance of each descriptor. 
The calculated F value for the generated QSAR model exceeds the tabulated F value by 
large margin as desired for a meaningful regression. Furthermore, the calculated F Value also 
determines a confidence limit superior to 95% for this model. The positive value of quality factor 
(Q) for QSAR model suggests its high predictive power and lack of over fitting, low standard 
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Table III.3: Experimental and predicted activities pIC50 of the molecules under study. 
Compound 
 
pIC50 Exp. pIC50pred. Resid. 
1 7.06 7.118 -0.058 
2 6.92 6.873 0.046 
3T 7.14 6.865 0.274 
4T 7.28 7.240 0.040 
5 7.25 7.165 0.084 
6 6.46 6.491 -0.031 
7 7.26 7.204 0.055 
8 7.02 7.216 -0.196 
9 7.04 6.951 0.088 
10 7.25 7.182 0.067 
11 7.41 7.372 0.037 
12 7.40 7.402 -0.002 
13 6.43 6.618 -0.188 
14 6.42 6.354 0.064 
15 7.07 6.951 0.118 
16T 7.08 6.327 0.752 
17 6.45 6.389 0.061 
18T 6.15 6.304 -0.154 
19 6.66 6.712 -0.053 
20 6.41 6.432 -0.022 
21 6.62 6.644 -0.025 
22 7.06 7.047 0.013 
23T 6.69 6.649 0.041 
24T 6.94 7.225 -0.285 
25T 5.21 5.147 0.062 
26 6.28 6.313 -0.033 
27 5.95 5.941 0.009 
28 5.70 5.683 0.016 
29 7.40 7.451 -0.051 
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The QSAR model expressed by (Eq.3) were cross validated by the high value ofRCV
2 = 0.973 
obtained by leave one out (LOO).The value of RCV
2  (Q2) is indeed greater than 0.5which is the 
essential condition to qualify a QSAR model as valid [19], and RMSE of cross-validation was 
0.078, which indicates reliability of the proposed model. 
The developed model were validated by calculation of the following statistical parameters: 
predicted residual sum of squares (PRESS), total sum of squares deviation (SSY), the predictive 
error of the coefficient of correlation (PE) and cross-validated correlation coefficients (R2adj and 
R2cv) (Table III.4). 
PRESS is an important cross-validation parameter as it is a good approximation of the real 
predictive error of the models. Its value being less than SSY points out that the model has a good 
predictive power and can be considered statically significant. The smaller PRESS value means the 
better model predictability.  
Table III.4:Cross-validation parameters. 
Model PRESS SSY PRESS/SSY S PRESS R2cv R2adj 6PE 
 0.135 4.963 0.027 0.077 0.973 0.948 0.023 
Furthermore, for reasonable QSAR model, the PRESS/SSY ratio should be lower than 0.4. 
[35].The data presented in (Table III.4) indicate that for the developed model this ratio is 0.027. 
The high value of   RCV
2  and R2adj are essential criteria for the best qualification of the QSAR 
model. 
The predictive error of the coefficient of correlation (PE) is yet another parameter used to 
evaluate the predictive power of the proposed models. We have calculated the PE value of the 
proposed model and they are reported in (Table III.4). For the developed model the condition R = 
0.986>6PE is confirmed and hence, they could be considered as good predictive power.  
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Figure III.3: Predicted plot versus experimentally observed anti-tubercular activity 
 
The plots of the predicted pIC50 versus the experimental pIC50, obtained by the MLR 
modeling, are demonstrated in (Figure III.3).The plots for this model show to be more 
convenient with R2 =0.973. 
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To investigate the presence of a systematic error in developing the QSAR models, 
the residuals of predicted values of the biological activity pIC50 was plotted against the 
experimental values (Table III.3), as shown in (Figure III.4).The propagation of the residuals 
on both sides of zero indicates that no systematic error exists, as suggested by Jalali-Heravi and 
Kyani [36].It indicates that this model can be successfully applied to predict the anti-
tubercular activity of this class of molecules. 
3.2.2 External Validation 
The model (Eq. 3) also passed successfully Tropsha’s[20] recommended tests for 
predictive ability: 
𝑅𝑝𝑟𝑒𝑑








  = −0.218 <  0.1 
k= 1.014      k'=0.983               (0.85 ≤ k ≤ 1.15) 
|𝑅0
2 − 𝑅′0
2| = 0.006 < 0.3 
 
The predicted values for the test set are given in (Table III.3) (Figure III.3).These 
results might be considered as an indicator of good external predictability. 
The built model produced good results for the training set and the test set. It is 
noteworthy, that the MLR equation has acceptable quality and can predict the activity of 
training and test set with RCV 
2 = 0.973 and Rpred
2 = 0.778, respectively. The plots of the 
predicted pIC50 versus the expérimental pIC50, obtained by the MLR modeling, are 
demonstrated in (Figure III.3). There fore; we conclude that the antitubercular activity is 
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The qualitative study of the relation structure-properties was applied on the series of 
amino-pyrimidinehas pharmacological activities. 
Compound 12 having higher value of acceptor sites of proton and LipE of the data 
set and was deemed to be the most optimal compound. The application of Lipinski and 
Veber rules on the studied amino-pyrimidine derivatives shows that all these compounds, 
theoretically, will not have problems with oral bioavailability. 
The QSAR analysis was conducted with a series of 29 amino-pyrimidine as 
mycobacterium tuberculosis (PknB) inhibitors, the model depending on the (eq.3). MLR is 
the best produced model with very good statistical fit as evident, R = 0.986 and 
F=39.341.The physicochemical molecular and Quantum descriptors were found to have a 
key role in governing the change in biological activity. The model was validated using 
LOO cross-validation, and external test set. It indicates the model can be successfully 
applied to predict the anti-tubercular activity of these classes of molecules.
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PknB is one of the most important serine/threonine protein kinases for 
Mycobacterium tuberculosis (TB) [1,2]. The intracellular domain of PknB has the main 
activity of the holoenzyme, and is able to autophosphorylate and combine with ATP and its 
analogues [3-6]. PknB plays an important part in the growth of TB, and is necessary for 
survival of TB [7-9]. Change of expression index or phosphorylation of PknB can give to 
alteration of growth rate and morphology of TB, due to the defects in cell wall synthesis 
and cell division [10-12].Because of the differences between PknB and the human protein 
kinases, it is widely accepted as the drug target for anti-TB. To date, several PknB 
inhibitors have been reported, and some of them have shown certain degree of anti-TB 
capability. Most of these compounds are aminopyrimidines, aminoguanidines and 
anthraquinones [13-19]. 
Computer aided method is a first approach to screening novel therapeutic agents and 
the discipline is an emerging strategy as it reduces many complexities of drug design 
process.  
The study of receptor-ligand interaction is a fundamental concept of rational drug 
design and the prediction of such interactions by molecular docking has increasing 
importance in the field of structure based drug discovery [20]. The screening of lead 
molecule with good therapeutic properties and drug likeness is a tedious task in drug 
discovery process. Computer aided method is an easy platform to search such kinds of 
biologically active compounds with favorable ADMET (Absorption, Distribution, 
Metabolism, Excretion and Toxicity). 
Molecular modeling of the amino-pyrimidine compounds based on their interactions 
with Mycobacterium tuberculosis PknB, using Molecular docking to determine the best 
ligands conformation when bound to the active site [21]. 
 Finally in silico, ADMET studies were performed on the best ligands to compare the 
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2 Material and methods 
2.1 Protein Preparation Structure 
The downloading of serine/threonine protein kinases for Mycobacterium tuberculosis 
PknB was made from the data base Brookhaven Protein Data Bank (www.rcsb.org/pdb) 
[22] (access code 2FUM)[23] . 
It is co-crystallized with inhibitors Mitoxantrone, 1,4-Dihydroxy-5,8-bis({2-[(2-
Hydroxyethyl)Amino]Ethyl}Amino)Anthra-9,10-Quinone(three-letter code: MIX). All the 
heteroatom's and coordinates are removed from the PDB file. 
The three-dimensional structure of 2FUMwas obtained by X-ray diffraction in 
complex with a selective inhibitor Mitoxantrone with EC Number: 2.7.11.1 chains 
(A,B,C,D)), resolution 2.89 Å, and R-value 0.218.  In this study we have taken a chain A, 
263residues and 1994 atoms. This allowed us to obtain the model shown in (Figure IV.1). 
 
Figure IV.1:Three-dimensional crystal structure of the target protein 
 
Ramachandran Plot 
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2.2 Ligands structure optimization 
Screened of 29 amino-pyrimidine derivatives as Mycobacterium tuberculosis PknB 
inhibitors was selected from the literature [13,14,25], were optimized before docking using 
MM+ force-field (rms= 0.01 Kcal/Å) and the semi-empirical PM3 method, both of which 
are implemented in HyperChem 8.08 software [26]. The resulting structures were saved in 
“.mol” file formats for molecular docking studies. The ligand structures of 29 amino-
pyrimidine derivatives (table 1) were made by Marvin Sketch17.1.2 software [27]. 
 
2.3 Molecular Docking 
Molegro Virtual Docker (MVD2012) software [28] is advanced docking analysis 
software used to predict protein-ligand interactions. The potential binding site of the target 
protein and lead candidates are identified by a molecular docking algorithm called Mol 
Dock. 
MVD works on the basis of MolDock SE search algorithm. The docking algorithm 
was set at a maximum iteration of 1500 with a simple evolution size of 50 and minimum of 
5 runs. The population size was set at 50 with energy threshold of 100 at each step. The 
least minute was set as 10 minutes, the torsions/translations/rotations of the ligand-protein 
interaction were tested and the one giving lower energies is chosen for further studies. The 
bond flexibility of the ligands was fixed, and the side chain flexibility of the amino acids in 
the binding cavity was set with a tolerance of 1.10 and strength of 0.90 for docking 
simulations. Root-mean-square deviation threshold for multiple cluster poses was set at 
<2.00 [29]. 
Different docking programs available and they differ in the nature of the sampling 
algorithms they employ, in their manner of handling ligand and protein flexibility, in the 
scoring functions and in the CPU time they required. In the studies reported here, MVD 
was used, because it showed higher docking accuracy when benchmarked against other 
available docking programs. (MD: 87%, Glide: 82%, Surflex: 75%, FlexX: 58%) have 
been shown to be successful in several recent studies, but also for reasons of cost and user 
friendliness. 
 Binding affinities were estimated using Molegro data Modeler The scoring function 
used by MolDock is derived from the piecewise linear potential scoring functions which 
further improves this score with a new H-bonding term and new charge schemes ,being 
flexible,i.e. all non-ring torsions were allowed [30]. 
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This molecular docking protocol generate five best predicted poses for each amino-
pyrimidine compound with Moldock score, Rerank score, and Hydrogen bond score. The 
docked conformations or pose with the minimum MolDock score values is the optimal 
pose.  
The docked conformation further analyzed on the basis of the Re-Rank score 
function. The Re-Ranking score function is generally more reliable than the MolDock 
scorefunction at selecting the best solution among multiple solutions derived from the 
same ligand [31]. 
Ligplot plus 1.4.5 [32], a program to generate schematic diagrams of protein ligand 
interactions. 
2.4 Drug Likeness and Pharmacokinetic Properties of selected ligands 
Physicochemical properties of interest included predicted lipophilicity (logP), 
predicted aqueous solubility (logS), topological polar surface area (TPSA), molecular 
weight (MW), hydrogen bond donor (HBD), hydrogen bond acceptor (HBA),  value 
predicted by Marvin Sketch. The calculation of partition coefficient was conducted by 
applying both consensus and ChemAxon methods as implemented in MarvinSketch. 
The ligands were predicted for drug likeliness, ADMET (adsorption, distribution, 
metabolism, excretion and toxicity studies by PreADMET [33].The main filters used for 
prediction of drug likeliness were Lipinski’s rule of five [34], CMC [35], MDDR [34], 
Lead-like Rule [36], and WDI (World drug index)-like rule[37].These rules were 
scrutinized and were subjected to ADME prediction.  
The pharmacokinetic parameters, absorption and distribution, were considered for 
selection of compounds as drug candidates. In this study, the PreADMET program was 
used to predict ADMET of amino-pyrimidine derivatives. The aspect prediction of 
absorption properties included percentage human intestinal absorption (% HIA) and Caco2 
(heterogeneous human epithelial colorectaladeno carcinoma), and MDCK, and MDCK 
(Madin-Darbycanine kidney) cell permeability [38]. And blood brain barrier 
prediction[39].Those molecules qualified the above rules based on specific statistical cut-
off available for each model was selected for toxicity prediction. However, virtual 
screening was also performed to evaluate toxicological properties including 
carcinogenicity and risk of inhibition of human ether-a-go-go-related (hERG) gene [33]. 
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These works have been performed by using Windows 7 64-bit operating system having 
Intel core 2duo processor. 
3 Results and discussion 
3.1 Validation of Model structures 
The stereo chemical quality of the predicted model was evaluated after the 
refinement process using Ramachandran Map calculations computed with the Procheck. 
The phi and psi distribution of the Ramachandran Map generated by non glycine and non 
proline residues are depicted in (FigureV.2) Ramachandran plot indicated that no residues 
have phi/psi angles in the disallowed regions and hence the quality of the model is 
acceptable. The percentage of residues in the “core” region of our modeled protein was 
found to be satisfactory [40]. 
The red regions in the graph indicate the most allowed regions whereas the yellow 
regions represent allowed regions. In this protein model, 86.6% of the residues were in the 
most favored region, 10.9% in allowed region, 1.8 % in generously allowed region and 

















Figure IV.2: Ramachandran plot for 2FUM protein generated by Procheck 
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3.2 Prediction of binding sites 
MVD automatically identifies potential binding sites (also referred as cavities or 
active sites) by using its cavity detection algorithm. The cavities within a 30 x 30 x 30 
Å3cube centered at the experimentally known ligand position were used. 
 In the case of the crystal structures for serine/threonine protein kinase B (2FUM). 
complexes, the program generally identified five different binding sites (Figure IV.3).From 
these five predicted cavities(Table IV.1) the one with the highest volume (107.52Å3) and 
surface(.295.69 Ǻ2), was selected for consideration, as it includes the bound ligand.  
 
Table IV.1: Cavity information of enzyme (2FUM.) 
Cavity Name Volume(Ǻ3) Surface Area(Ǻ2) 
 
Cavity 1 107.52 295.69 
Cavity 2 59.392 170.24 
Cavity 3 23.040 96 
Cavity 4 16.896 80.64 
Cavity 5 16.384 70.4 
 
The binding site was defined as a spherical region which encompasses all protein atoms 
within 6.0 A° of bound crystallographic ligand atom dimensions X (61.79 A°), Y (2.44 
A°), Z (-25.10A°) axes, respectively). Default settings were used for all the calculations.  
 
Figure IV.3: The five cavities MVD- detected cavities in PknB, PDB code; 2FUM .  
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3.3 Protein-Ligand Docking: 
One application of molecular docking is to design pharmaceutical in silico by 
optimizing targeted lead candidates against protein. The lead candidates can be found 
using a docking algorithm that aims to identify the optimal binding mode of asmall 
molecule (ligand) to the active site of macromolecular target. Ligands have been designed 
to obtain more potent compounds as inhibitors of PknB. 
Computational analysis was carried out on chain A of the enzyme 2FUM. The 29 
ligands L1-29 were selected for the study of the protein-ligand interactions, five top poses 
for each ligand were returned in the simulation, out of which one best pose for each ligand 
was selected on the basis of their MolDock score.The MVD score and the re-rank score 
sand H-Bound score (KJ/mol), for each docking studies of amino-pyrimidine ligands with 
2FUM are summarized in (Table IV.2). 
The docking of ligands outcome produced the three best ranked ligands, namely, L9, 
L12and L21, which showed lower Moldock score, re-rank score and a higher number of 
hydrogen bonding interaction than the other compounds. The binding energy values of 
compounds L9, L12and L21 are-161.475, -152.003 and-143.359 kcal/mol, respectively, 
which are better than MIX with binding energy value of -75.683  kcal/mol. These results 
show that, compared to MIX as selective PknB, those three top-ranked ligand swill form 
more stable complex and selective with, as²well as, be better able to inhibit and reduce the 
activity of PknB.  
 















-147.646 -69.264 -2.276 
2 
 
-144.615 -95.918 -2.014 
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-139.421 -116.664 -6.416 
4 
 
-139.71 -29.120 -5.586 
5 
 
-155.848 -96.502 -7.761 
6 
 
-147.347 -109.939 0 
7 
 
-155.794 -120.147 -2.618 
8 
 
-142.356 -90.290 -2.009 
9 
 
-161.475 -128.826 -7.237 
10 
 
-153.264 -116.047 -0.639 
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-151.906 -119.35 -2.961 
12 
 
-152.003 -126.941 -8.380 
13 
 
-123.111 -99.842 -4.821 
14 
 
-140.882 -112.329 -5.180 
15 
 
-133.398 -105.768 -4.163 
16 
 
-127.542 -94.644 -2.693 
17 
 
-134.871 -96.723 -2.636 
18 
 
-135.756 -100.839 -7.316 
19 
 
-125.914 -95.786 -7.169 
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-143.71 -112.077 -5.767 
21 
 
-143.359 -120.853 -9.685 
22 
 
-133.614 -107.115 -4.613 
23 
 
-120.633 -99.877 -5.483 
24 
 
-135.237 -106.568 -5.233 
25 
 
-134.254 -62.821 -1.500 
26 
 
-156.908 -93359 -1.364 
27 
 
-170.109 -94.358 -3.122 
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Hydrogen bonds are key players and directly responsible for affinity and specificity in the 
protein-ligand complexes. Thus, to evaluate the binding affinity of the ligands with the 
target protein, therefore number of hydrogen bonds between ligands and amino acid of the 
target protein indicate it stability to inhibit the protein target. 
* Ligand 21, the most active ligand, formed six hydrogen bonds, and interacted with the 
Gly93, Val95, Lys140 and Asn143 active amino acid residues. Gly93 formed H-bonds 
with NH group of  Pyrazole ring and Val 95 formed tow hydrogen bonds with the N atom 
and the −NH group of  Pyrazole ring, Lys140  forms two H-bonds  with the two O (oxygen 
diatom) of the sulfonylmethane group and Asn143 formed H-bonds with the hydrogen 
atom of  O (oxygen diatom) of the sulfonyl group. 
* Ligand 12 is the second most active ligand; it forms five hydrogen bonds, and interacted 
with the Gly93, Val95, Leu17 and Tyr 94 active amino acid residues. Gly93 formed H-
bonds with NH group of pyrazole ring, whereas Val 95 formed two hydrogen bonds with 
the N atom and the −NH group of the pyrazole ring. Leu 17 and Tyr 94 formed 
respectively one H-bond with NH group and  one H-bond with the H-bond atom of O 
(oxygen diatom) of the sulfonyl group. 
* Ligand 9 is the less most active ligand; it forms three hydrogen bonds, and interacted 
with the Gly93 and Val95 active amino acid residues, respectively. Gly93 formed one H-
28 
 
-138.238 -111.629 0 
29 
 
-136.307 -108.308 -2.035 
MIX 
 
-75.683 -17.158 -6.501 
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bond with the NH group of pyrazole ring whereas Val 95 formed two hydrogen bonds with 
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Figure IV.4: Hydrogen bonds interaction between ligands L9 (A), L12 (B), L21(C) and  
MIX ( D) and residues of active site of 2FUM. 
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L 9 0 H 2.60 90 691 Gly93 O 
1 N 2.63 92 709 Val95 H 
9 H 3.06 92 712 Val95 O 
L 12 13 H 2.63 90 691 Gly93 O 
14 N 2.61 92 709 Val95 H 
9 H 2.69 92 712 Val95 O 
22 H 2.83 14 116 Leu17 O 
60 O 2.60 91 708 Tyr94 H 
L 21 13 H 2.84 90 691 Gly93 O 
12 N 2.73 92 709 Val95 H 
9 H 3.12 92 712 Val95 O 
45 O 3.15 137 1058 Lys140 H 
43 O 3.23 137 1058 Lys140 H 
43 O 3.16 140 1078 Asn143 H 
 
  The lengths of the hydrogen bonds in the interval: 2.5Å ≤ x ≤ 3.1Å are considered 
strong interactions; however values in the interval 3.1Å≤ x≤3.55Å: the averages 
interactions, whereas values > 3.55Å are considered weak. It is noticed that the values 
obtained for distances of hydrogen bonds between the ligands L9, L12 and the residues of 
active site belong to the interval 2.5Å ≤ x ≤ 3.1Å. These results indicate that the strong 
affinity of L9 and L12 on 2FUM could lead to the potent inhibition of the catalytic activity 
of the enzyme [41]. 
LigPlot is known as the comprehensive tool for expressing the hydrogen bonding and 
hydrophobic interactions involving the ligand molecule and active site residues (Figure 
IV.5) gives a more detailed insight of the interactions with particular amino acids in 
enzyme binding pocket. Based on the presented results, it can be concluded that 
hydrophobic interactions between ligands L9, L12, L21 and binding pocket play an 
important role. However, number, bond length and bond energy of hydrogen bonds formed 
between ligand and enzyme has an important role in ligand effect on investigated activity. 
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Figure IV.5: LigPlot generated for the best poses obtained with ligands L9 (A), L12 (B), 
L21 (C) and receptor 2FUM. 
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3.4 Drug-likeness and ADMET Properties of selected ligands  
3.4.1 Drug-likeness of selected ligands 
The selected ligands used in this study were evaluated as selective inhibitor 2FUM 
protein target by comparison. The oral bioavailability of the compounds projected as 
potential drugs were evaluated by determining the molecular weight, number of rotatable 
bonds , H bond donor and acceptor, and drug’s polarsurface (TPSA). Since the individual 
molecular weights of all the compounds were less than 500, the numbers of the rotatable 
bond were <10, the number of hydrogen bond donors and acceptors were < 10, an octanol-
water partition coefficient logP not greater than 5. TPSA values being <140, they qualified 
to be an ideal oral drug. Ligands tested inthis study were also predicted to have good oral 
bioavailability and all the ligand qualify of the Lipinski’s Rule of 5. 
According to (Table IV.4), all the ligands possess limited aqueous solubility which 
ranged from very slightly soluble to practically insoluble [42]. This result is also supported 
by the calculation of partition coefficient which indicates that all the tested compounds are 
lipophilic and have the best affinity to reside in n-octanol than in water i.e. all the ligands 
will pass the plasma membrane easily (Table IV.4). 
Table IV.4: Physicochemical property of anti-tubercular ligands. 
 
In drug-likeness prediction, a molecule can be considered to have drug-like features 
Only if it satisfies most of the rules including rule of five, CMC-like rule, MDDR-like rule, 
Lead-like rule, WDI-like rule. All of the selected ligands qualified Lipinski’s rule, WDI 
rule as it was in the cut-off range (90%) and CMC-like rule expectedL12 and MIX, such as 
MIXMDDR rule, whereas L9, L12, L21 showed mid-structure to MDDR-like rule. 





















L9 414.517 -5.95  4.81 2 8 96.76 
L12 481.62 -4.87  3.55 3 9 115.90 
L21 398.49 -4.65  2.88 3 8 112.66 
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Table IV.5: Drug likeness prediction using PreADMET Server 








L9 Qualified Violated Suitable Out of 90 %  Mid-structure 
L12 Not Qualified Violated Suitable Out of 90 %  Mid-structure 
L21 Qualified Violated Suitable Out of 90 %  Mid-structure 
MIX Not Qualified Violated Suitable Out of 90 %  Drug-like 
 
3.4.2 ADMET study of selected ligands 
The pharmacokinetic studies such as absorption, distribution of L9, L12, L21 and 
MIX were performed using online server PreADMET (https://preadmet.bmdrc.kr/). The 
calculated absorption, distribution parameters are presented in (Table IV.6). The calculated 
human intestinal absorption (HIA) was ranged from 85.48% to 90.926 % which suggest 
that all the tested compounds are well absorbed through the intestinal cell [43]. 























































































































































L9 90.926 15.148 -3.721 82.193 1.141 Inhibitor 
L12 89.806 1.605 -2.642 87.243 0.292 Inhibitor 
L21 85.480 6.312 -2.704 93.097 0.118 Non inhibitor 
MIX 24.710 18.258 -5.094 22.314 0.029 Non inhibitor 
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In addition, all compounds exhibited high permeability [44] as absorption values 
through Caco-2 cell (PCaco-2) were within 15.148 - 6.312 nm/s excepted l9 (1.605 
nm/s).The skin permeability (PSkin) is a vital parameter for the assessment of drugs and 
chemical that might require transdermal administration. All the compounds were found to 
be impermeable through skin since the calculated PSkin value was negative. 
The distribution properties were assessed by evaluating the brain to blood partition 
coefficient (Cbrain/Cblood), plasma binding (PPB) and interaction with the P-glycoprotein 
(Pgp). The calculated values of PPB were 82.193 to 93.097 %. Generally compounds with 
more than 90% of PPB are classified as strongly bound chemicals whereas less than 90% 
are weakly bound chemicals (https://preadmet.bmdrc.kr/adme-prediction/). Therefore, 
among L21 bound strongly with plasma protein whereas L9and L12 are weakly bound 
chemicals. The Cbrain/Cblood values were 0.118 to 1.141. Based on Cbrain/Cblood ratio 
all chemicals fall under three categories namely high absorption to CNS (Cbrain/Cblood 
value more than 2.0), middle absorption to CNS (Cbrain/Cblood value within 2.0 - 0.1) and 
low absorption to CNS (Cbrain/Cbloodvalue less than 0.1). The ratio of Cbrain/Cblood 
suggests middle absorption of these agents to CNS indicating moderate to higher ability to 
cross blood brain barrier (BBB).P-glycoprotein (Pgp), produced from the multi drug resistance 
(MDR) gene and an ATP dependent efflux transporter that affects the absorption, distribution and 
excretion of clinically important drugs [45]. 
The ligands L9 and L12 are inhibitors for Pgp and L21 is not inhibitors for Pgp. 
Ligand L21 showed PPB=93.097%, HIA= 85.48 and cell permeability =6.312nm/s, this 
ligand will be with greater availability to bind with the target receptor when compared to 
other compounds. (Table IV.7) shows the results of mutagenic (Ames test) and carcinogenic 
(using mouse and rat model) properties of L9, L12, L21 and MIX. Toxicological investigation of 
drug candidates is one of the key steps for drug discovery. This means that the toxicity study is 
very important for new compounds.  
The Ames test is widely used and an accepted test to evaluate the mutagenicity of a 
chemical agent. In this test, all the compounds exhibited negative prediction mutagenic 
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L9 mutagen Negative 
 
Negative Medium risk 
















In carcinogenicity study, the PreADMET server was utilized to predict the 
carcinogenicity of chemical agent. In the prediction of carcinogenicity, negative prediction 
indicates there is evidence of carcinogenic activity whereas positive means the tested 
compound does not exhibit carcinogenic activity. Among all ligands demonstrated 
carcinogenicity in both mouse and rat model. The risk of inhibition of human ether-a-go-
go-related (hERG) gene was varied from medium and ambiguous.  
 
4 Conclusion 
Virtual screening methods are widely used for reducing cost and time of drug discovery 
process. From this study of in silico drug designing and molecular docking of the 29 
amino-pyrimidine derivatives, we conclude that those derivatives have the ability to inhibit 
the Mycobacterium tuberculosis protein kinase B.  The scoring results reveal the higher 
negative mol dock score, rerank score and hydrogen bond interaction of the title 
compounds in comparison to MIX .It was found that the three ligands L9, L12, L21 showed 
better results from 29 docked ligands. Furthermore, Pharmacokinetic effects of the ligand 
L21 observed comparatively better bioavailability, distribution, absorption, than MIX and 
other ligands. Hence, it could be concluded that the ligand L21 could be considered as 
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In this work, we have used several computational techniques that have been 
designed to aid early drug discovery in a setting with limited prior information. They 
have also been applied to improve our understanding of the requirements for binding 
of a target, and to identify small molecule inhibitors of the potential anti-TB.  
The first part, we have studied the structure-activity relationship (SAR) and 
drug likeness proprieties of a bioactive series of amino-pyrimidine derivatives have 
shown that structural units involved in the biological activity. In our case, the Lipinski 
and Veber rules are validated. Therefore, theoretically, all compounds will not have a 
problem with oral bioavailability. 
Next to, we have applied Quantitative structure activity relationship (QSAR) 
analysis to a series of 29 amino-pyrimidine as PknB inhibitors using a combination of 
various physicochemical and quantum descriptors. A multiple linear regression 
(MLR) procedure was used to model the relationships between molecular descriptors 
and the chemotherapeutic activity of the amino-pyrimidine derivatives. Good 
agreement between experimental and predicted activity values, obtained in the 
validation procedure, indicated the good quality of the derived QSAR model. The best 
QSAR model developed show a good predictive correlation coefficient R2= 0.973 and 
external predictive ability of prediction Rtest
2=0.778 was developed by MLR. The 
proposed model has good robustness and predictability when verified by internal and 
external validation. 
In the second part, the docking study using Molegro Virtual Docker has been 
performed on these predicted compounds to find their interactions with the receptor 
PDB (2FUM). We have selected three best ranked ligands L9, L12 and L21, which 
showed lower Moldock Score, re-rank score and a higher number of hydrogen 
bonding interaction than the other compounds. 
In silico ADMET predictions in PreADMET server revealed that except L21 
compound had good absorption as well as solubility characteristics and had minimal 
toxic effects. It could be concluded that the ligand L21 could be considered as potent 







In this research we conclude that computational chemistry is of great 
importance in the diagnosis of large and small molecules. There are several 
approaches in which to diagnose these compounds. Computational chemistry has an 
importance in medicine, diagnosis and discovery of drugs and the importance of the 




The discovery of anti-tuberculosis agents is crucial for effective tuberculosis therapy. 
The present strategy for new drug development is directed towards identifying essential 
enzyme systems in the bacteria and developing potent molecules to inhibit them.We have 
study the inhibition of 29 amino-pyrimidine derivatives of Mycobacterium tuberculosis 
PKnB using different CADD approaches to search for potential drug candidates. 
The multi-parameter optimization (MPO) process to predict the best balance of 
properties of these compounds was expressed by various approaches such as Lipophilic 
Efficiency (LipE), Lipinski, Veber rules. The Multiple linear regression method (MLR) was 
applied to derive QSAR model which was further validated for statistical significance by 
internal and external validation. In Silico molecular docking and ADMET properties used to 
predict novel PKnB inhibitors and guide the discovery of new potential analogs. 
Keywords: anti-tuberculosis, CADD, MPO, MLR, QSAR, docking, ADMET. 
 
Résumé : 
La découverte d’agents antituberculeux est cruciale pour un traitement efficace de la 
tuberculose. La stratégie actuelle de développement de nouveaux médicaments vise à 
identifier les systèmes enzymatiques essentiels dans les bactéries et à développer des 
molécules puissantes pour les inhiber.Nous avons étudié l’inhibition de 29 dérivés d’amino-
pyrimidine de Mycobactérie tuberculoses PKnB en utilisant différentes approches CADD 
pour la recherche de candidats médicaments. 
Le processus d'optimisation multi-paramètres (MPO) permettant de prédire le meilleur 
équilibre des propriétés de ces composés a été exprimé par des diverses approches telles que 
les règles Efficacité lipophylique de ligand (LipE), Lipinski, Veber. La méthode de 
régression linéaire multiple(MLR)a été appliquée pour dériver de modèle QSAR qui a ensuite 
été validés pour la signification statistique par validation interne et externe. In Silico, les 
propriétés de doking moléculaire et ADMET sont utilisées pour prédire de nouveaux 
inhibiteurs de la PKnB et guider la découverte de nouveaux analogues potentiels. 
Mots clés : antituberculeux, CADD, MPO, MLR, QSAR, docking, ADMET. 
 
صخلم 
فاشتكا لالماوع لاةداضم لسلل رمأ غلاب ةيمهلأا جلاعل لسلا .لاعفلافدهت ةيجيتارتسلإا ةيلاحلا ريوطتل ةيودأةديدج و ديدحت
طيبثتل ةيول تائيزج ريوطتو ايريتكبلا يف ةيساسلأا تاميزنلإا ةمظنأاه. ةساردب انمل دمل92 كتشم نيديميرب ونيما  
  نع ثحبللنسحأ  حشرمكءاود. CADD    فلتخم مادختساب لسلا ةرطفتمللجهانم ( amino- Pyrimidine) 
 نيسحتلا ةيلمع نع ريبعتلا متددعتملاةلاعلماو(MPO)  تابكرملا هذه صئاصخل نزاوت لضفأب ؤبنتلل  نم للاخ
لثم ةفلتخم قرط ةءافك نوهدلا.Veber, Lipinski, (LipE) مت يبطتقامتشلا ددعتملا يطخلا رادحنلاا ةميرط ك  جذومن
QSAR  هتحص نم كمحتلا مت يذلاوقرط لامعتساب ةيئاصحإ تمبط ليجراخلاو يلخادلا كمحتل.  صئاصخ مدختُست
ماحتللاا يئيزجلا  docking و ADMET ـل ةديدج تاطبثمب ؤبنتلل PKnB فاشتكا هيجوتو تابكرم ةديدج .ةلثامم 
 
ADMET,  يئيزجلا   ماحتللاا, MLR, QSAR, MPO,CADD ,  لاةداضم لسلل :ةلادلا تاملكلا 
